WO2015157399A1 - Transgene genetic tags and methods of use - Google Patents

Transgene genetic tags and methods of use Download PDF

Info

Publication number
WO2015157399A1
WO2015157399A1 PCT/US2015/024895 US2015024895W WO2015157399A1 WO 2015157399 A1 WO2015157399 A1 WO 2015157399A1 US 2015024895 W US2015024895 W US 2015024895W WO 2015157399 A1 WO2015157399 A1 WO 2015157399A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
alternatives
seq
domain
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/024895
Other languages
English (en)
French (fr)
Other versions
WO2015157399A9 (en
Inventor
Michael C. Jensen
Adam Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seattle Childrens Hospital
Original Assignee
Seattle Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54288361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2015157399(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2945308A priority Critical patent/CA2945308C/en
Priority to EP21180797.9A priority patent/EP3954708A1/en
Priority to EP15776745.0A priority patent/EP3129405B1/en
Priority to BR112016023507-0A priority patent/BR112016023507B1/pt
Priority to JP2016561722A priority patent/JP6772068B2/ja
Priority to KR1020167031068A priority patent/KR102387243B1/ko
Priority to US15/302,420 priority patent/US10611837B2/en
Priority to AU2015243849A priority patent/AU2015243849B2/en
Priority to MYPI2016703721A priority patent/MY184163A/en
Priority to SG11201608393TA priority patent/SG11201608393TA/en
Priority to RU2016143384A priority patent/RU2729112C2/ru
Priority to CN201580030814.2A priority patent/CN106536558A/zh
Priority to PH1/2016/502011A priority patent/PH12016502011B1/en
Priority to ES15776745T priority patent/ES2867224T3/es
Priority to KR1020227011931A priority patent/KR102600544B1/ko
Priority to NZ725079A priority patent/NZ725079A/en
Priority to IL248238A priority patent/IL248238B2/en
Priority to MX2016013160A priority patent/MX387465B/es
Application filed by Seattle Childrens Hospital filed Critical Seattle Childrens Hospital
Publication of WO2015157399A1 publication Critical patent/WO2015157399A1/en
Anticipated expiration legal-status Critical
Priority to ZA2016/07061A priority patent/ZA201607061B/en
Publication of WO2015157399A9 publication Critical patent/WO2015157399A9/en
Priority to US16/794,673 priority patent/US11414486B2/en
Priority to AU2021201679A priority patent/AU2021201679B2/en
Priority to US17/812,848 priority patent/US12448445B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/002—Vectors comprising a special origin of replication system inducible or controllable
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Definitions

  • the present invention relates to the compositions and methods useful for detecting transgene expression in cells.
  • transgenes in cells are becoming an important therapeutic approach for a variety of conditions.
  • human T lymphocytes are engineered by gene transfer to express chimeric antigen receptors (CARs) specific for surface molecules expressed on tumor cells.
  • Chimeric receptors are synthetic receptors that include an extracellular ligand binding domain, most commonly a single chain variable fragment of a monoclonal antibody (scFv) linked to intracellular signaling components, most commonly CD3 ⁇ alone or combined with one or more costimulatory domains.
  • Other examples of conditions treated with transgene modified cells include thalassemia, hemophilia, myocardial infarction, and severe combined immunodeficiency.
  • a major issue remains with obtaining stable expression of transgene expression at levels comparable to endogenous genes.
  • compositions and methods for selecting and/or detecting cells that express transgenes at high levels are identified.
  • a genetic tag comprises an epitope based on human Her2, designated Her2t.
  • Her2t is devoid of all Her2 intracellular components, yet contains the Her2 transmembrane region, a conformationally intact epitope recognized by the monoclonal antibody trastuzumab (Herceptin) and a peptide to facilitate surface expression.
  • Her2t constructs Three variants of the Her2t construct, one containing the full Her2 Domain IV and two conformational epitopes that were designed based on the three-dimensional structure of Her2 in complex with Herceptin (Garrett et al J. Immunology 178:7120 (2007); Cho et al 2003), were incorporated into the lentiviral packaging plasmid epHIV7 and characterized in CHO cells.
  • Her2t as a genetic tag allows for the ex vivo selection and purification of homogenous populations of cellular therapeutics that express a transgene of interest.
  • Her2t can be used to track cellular therapeutics in vivo; for instance, Her2t can be used as a target for Herceptin staining of blood, bone marrow and cerebrospinal fluid aspirates to check for the persistence of transgene-expressing cellular therapeutics to follow cancer remission to therapeutic persistence in a patient.
  • Her2t extends the therapeutic reach of CAR therapy by allowing for the concerted purification of cells expressing multiple transgenes when used with another genetic tag such as EGFRt.
  • the disclosure provides an isolated polypeptide comprising at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids of 511 to 652 or 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2. Nucleic acids coding for the isolated polypeptide are included herein.
  • host cells comprising the nucleic acid coding for an isolated polypeptide comprising at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 511to 562 or 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, and wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2.
  • Host cells can be selected from the group consisting of CD8 T cells, CD4 T cells, CD4 na ' ive T cells, CD8 na ' ive T cells, CD8 central memory cells, CD4 central memory cells, and combinations thereof.
  • Host cells can further comprise a second nucleic acid coding for a second chimeric antigen receptor linked to a second genetic tag.
  • the second nucleic acid can be introduced into the same host cells as a nucleic acid coding for an isolated polypeptide comprising at least 95% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 511 to 562 or 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2.
  • the second nucleic acid is introduced into a second host cell population and at least the two host cell populations are combined into a single composition.
  • the T cells comprise precursor T cells.
  • the precursor T cells are hematopoietic stem cells.
  • a method comprises introducing an isolated nucleic acid, such as a nucleic acid coding for an isolated polypeptide comprising at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain (ECD) of HER2 polypeptide having a sequence of amino acids 511 to 652 or 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, into a host cell; and culturing the host cells in a medium comprising at least one growth factor.
  • ECD extracellular domain
  • a method further comprises selecting the host cells for expression of ECD before or after or both before and after the culturing step.
  • a method of manufacturing further comprises introducing a second nucleic acid coding for a second chimeric antigen receptor and a second genetic tag into the host cell.
  • the method further comprises selecting the host cells for expression of the second genetic tag before or after or both before and after the culturing step.
  • a method comprising introducing a first isolated nucleic acid, such as a nucleic acid coding for an isolated polypeptide comprising at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 511 to 652 or 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, into a first host cell; selecting first host cells that express ECD, introducing a second nucleic acid coding for a second chimeric antigen receptor and a second genetic tag into a second host cell, selecting second host cells for expression of the second genetic tag, and optionally, culturing the first and second host cells in a medium comprising at least one growth factor.
  • a composition comprises a first and second host cell population.
  • compositions for treating cancer tracking the cells of the composition in vivo, and killing the cells of the composition in vivo.
  • a method is provided wherein the method comprises treating a patient having cancer and expressing a tumor antigen, wherein the method further comprises administering an effective amount of a composition of host cells comprising one or more nucleic acids coding for a chimeric antigen receptor linked to a genetic tag.
  • the host cells of the composition comprise a first nucleic acid coding for a first chimeric antigen receptor linked to a first genetic tag and a second nucleic acid coding for a second chimeric antigen receptor linked to a second genetic tag.
  • the method further comprises administering an antibody or antigen binding fragment thereof that specifically binds to the genetic tag.
  • an antibody is administered that binds to the first genetic tag, an antibody is administered that specifically binds to the second genetic tag, or both administered.
  • the antibody is labelled with a detectable label, a cytotoxic agent, or both.
  • an isolated polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2.
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23. In some alternatives, the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23. In some alternatives, the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23. In some alternatives, the isolated polypeptide further comprises a leader peptide that provides for cell surface expression. In some alternatives, the leader peptide has the sequence of SEQ ID NO: 17. In some alternatives, the antibody is trastuzumab.
  • an isolated polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER, and wherein the extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 is linked to the transmembrane domain by a sequence comprising amino acids GGGSGGGS (SEQ ID NO: 45).
  • an isolated nucleic acid wherein the isolated nucleic acid encodes a polypeptide.
  • the isolated polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2.
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23. In some alternatives, the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23. In some alternatives, the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23. In some alternatives, the isolated polypeptide further comprises a leader peptide that provides for cell surface expression. In some alternatives, the leader peptide has the sequence of SEQ ID NO: 17. In some alternatives, the antibody is trastuzumab.
  • the isolated polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER, and wherein the extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 is linked to the transmembrane domain by a sequence comprising amino acids GGGSGGGS (SEQ ID NO: 45).
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23. In some alternatives, the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23. In some alternatives, the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23. In some alternatives, the isolated polypeptide further comprises a leader peptide that provides for cell surface expression. In some alternatives, the leader peptide comprises an amino acid sequence set forth in SEQ ID NO: 17. In some alternatives, the antibody is trastuzumab. In some alternatives, the isolated nucleic acid further comprises a promoter.
  • the isolated nucleic acid further comprises a transgene.
  • the transgene comprises a polynucleotide encoding a chimeric antigen receptor.
  • the chimeric antigen receptor comprises an antigen binding domain, a spacer domain, a transmembrane domain and at least one stimulatory domain.
  • the polynucleotide encoding the transgene is linked to the nucleic acid encoding the HER2 polypeptide with a self-cleaving linker.
  • the HER2 polypeptide comprises at least 95%, 96%>, 97%, 98%>, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2.
  • the self-cleaving linker is a T2A linker having the sequence of LEGGGEGRGSLLTCG (SEQ ID NO: 26).
  • the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 2.
  • the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 25 (CD20CAR).
  • a host cell comprising an isolated nucleic acid, wherein the isolated nucleic acid encodes a polypeptide.
  • the isolated polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2.
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23. In some alternatives, the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23. In some alternatives, the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23. In some alternatives, the isolated polypeptide further comprises a leader peptide that provides for cell surface expression. In some alternatives, the leader peptide has the sequence of SEQ ID NO: 17. In some alternatives, the antibody is trastuzumab.
  • the isolated polypeptide comprises at least 95%, 96%, 97%), 98%o, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER, and wherein the extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 is linked to the transmembrane domain by a sequence comprising amino acids GGGSGGGS (SEQ ID NO: 45).
  • the isolated nucleic acid further comprises a transgene.
  • the transgene comprises a polynucleotide encoding a chimeric antigen receptor.
  • the chimeric antigen receptor comprises an antigen binding domain, a spacer domain, a transmembrane domain and at least one stimulatory domain.
  • the polynucleotide encoding the transgene is linked to the nucleic acid encoding the HER2 polypeptide with a self-cleaving linker.
  • the HER2 polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2.
  • the self-cleaving linker is a T2A linker having the sequence of L E G G G E G R G S L L T C G (SEQ ID NO: 26).
  • the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 2. In some alternatives, the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 25 (CD20CAR).
  • the host cell is selected from the group consisting of CD8 T cells, CD4 T cells, CD4 naive T cells, CD8 naive T cells, CD8 central memory cells, CD4 central memory cells, and combinations thereof. In some alternatives, the host cell is autologous. In some alternatives, the host cell is antigen specific. In some alternatives, the host cells are precursor T cells. In some alternatives, the host cells are hematopoietic stem cells.
  • a composition comprising host cells wherein the host cells comprise an isolated nucleic acid, wherein the isolated nucleic acid encodes a polypeptide.
  • the isolated polypeptide comprises at least 95%, 96%, 97%), 98%o, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2.
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23. In some alternatives, the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23. In some alternatives, the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23. In some alternatives, the isolated polypeptide further comprises a leader peptide that provides for cell surface expression. In some alternatives, the leader peptide has the sequence of SEQ ID NO: 17. In some alternatives, the antibody is trastuzumab.
  • the isolated polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER, and wherein the extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 is linked to the transmembrane domain by a sequence comprising amino acids GGGSGGGS (SEQ ID NO: 45).
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23. In some alternatives, the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23. In some alternatives, the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23. In some alternatives, the isolated polypeptide further comprises a leader peptide that provides for cell surface expression. In some alternatives, the leader peptide comprises an amino acid sequence set forth in SEQ ID NO: 17. In some alternatives, the antibody is trastuzumab. In some alternatives, the isolated nucleic acid further comprises a promoter.
  • the isolated nucleic acid further comprises a transgene.
  • the transgene comprises a polynucleotide encoding a chimeric antigen receptor.
  • the chimeric antigen receptor comprises an antigen binding domain, a spacer domain, a transmembrane domain and at least one stimulatory domain.
  • the polynucleotide encoding the transgene is linked to the nucleic acid encoding the HER2 polypeptide with a self-cleaving linker.
  • the HER2 polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2.
  • the self-cleaving linker is a T2A linker having the sequence of L E G G G E G R G S L L T C G (SEQ ID NO: 26).
  • the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 2. In some alternatives, the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 25 (CD20CAR).
  • the host cell is selected from the group consisting of CD8 T cells, CD4 T cells, CD4 na ' ive T cells, CD8 naive T cells, CD8 central memory cells, CD4 central memory cells, and combinations thereof. In some alternatives, the host cell is autologous. In some alternatives, the host cell is antigen specific. In some alternatives, the host cells are precursor T cells. In some alternatives, the host cells are hematopoietic stem cells.
  • a method of manufacturing a composition comprising introducing an isolated nucleic acid into a host cell and culturing the host cells in a medium comprising at least one growth factor.
  • the isolated nucleic acid encodes a polypeptide.
  • the isolated polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2.
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23.
  • the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23.
  • the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23.
  • the isolated polypeptide further comprises a leader peptide that provides for cell surface expression.
  • the leader peptide has the sequence of SEQ ID NO: 17.
  • the antibody is trastuzumab.
  • the isolated polypeptide comprises at least 95%, 96%>, 97%, 98%>, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER, and wherein the extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 is linked to the transmembrane domain by a sequence comprising amino acids GGGSGGGS (SEQ ID NO: 45).
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23. In some alternatives, the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23. In some alternatives, the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23. In some alternatives, the isolated polypeptide further comprises a leader peptide that provides for cell surface expression. In some alternatives, the leader peptide comprises an amino acid sequence set forth in SEQ ID NO: 17. In some alternatives, the antibody is trastuzumab. In some alternatives, the isolated nucleic acid further comprises a promoter.
  • the isolated nucleic acid further comprises a transgene.
  • the transgene comprises a polynucleotide encoding a chimeric antigen receptor.
  • the chimeric antigen receptor comprises an antigen binding domain, a spacer domain, a transmembrane domain and at least one stimulatory domain.
  • the polynucleotide encoding the transgene is linked to the nucleic acid encoding the HER2 polypeptide with a self-cleaving linker.
  • the HER2 polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2.
  • the self-cleaving linker is a T2A linker having the sequence of L E G G G E G R G S L L T C G (SEQ ID NO: 26).
  • the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 2. In some alternatives, the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 25 (CD20CAR).
  • the host cell is selected from the group consisting of CD8 T cells, CD4 T cells, CD4 naive T cells, CD8 naive T cells, CD8 central memory cells, CD4 central memory cells, and combinations thereof. In some alternatives, the host cell is autologous. In some alternatives, the host cell is antigen specific. In some alternatives, the growth factor is selected from the group consisting of IL-15, IL-7, IL-21, IL-2, and combinations thereof. In some alternatives, the method further comprises selecting cells that express the Her2t polypeptide.
  • the cells are selected before culturing the cells in the medium. In some alternatives, the cells are selected using an antibody that binds to Domain IV of Her2. In some alternatives, the antibody is trastuzumab. In some alternatives, the method further comprises introducing a second isolated nucleic acid coding for a chimeric antigen receptor linked to a second genetic tag. In some alternatives, the method further comprises selecting cells expressing the second genetic tag. In some alternatives, the second genetic tag comprises EGFRt. In some alternatives, the host cells are precursor T cells. In some alternatives, the host cells are hematopoietic stem cells.
  • FIG. 1 Structural schematic of Her2t.
  • Panel A Molecular model of the extracellular and transmembrane regions of Her2t (middle) versus Her2 (ErbB2; left). Her2t in complex with Herceptin Fab (right).
  • Panel B Schematic of Her2t containing leader peptide composed of the GMCSF receptor-a chain signal sequence (GMCSFRss) to allow for surface expression. The remaining Her2t sequence is composed of an epitope of Her2 (ErbB2) Domain IV (89 aa) and a 23-aa transmembrane region.
  • GMCSFRss GMCSF receptor-a chain signal sequence
  • Her2t was cloned in frame downstream to the CAR and T2A to allow for co-expression.
  • Figure 2 Her2t partners with trastuzumab (Herce tin) to immunomagnetically enrich Her2t-expressing cells.
  • Patent B Her2t-transduced K562 cells pre- and post-selection using biotinylated Herceptin and anti-biotin microbeads (Miltenyi). Cells purified up to 95% Her2t positive.
  • FIG. 1 The epitope of Her2t is specifically recognized by Herceptin and goes unrecognized by commercial Her2t antibodies.
  • FIG. 1 Western blot analysis using a commercial antibody (top) or biotinylated Herceptin (bottom) exemplifying the difference in kDa size between Her2t (25kDa) and ErbB2 (250kDa). Lanes from left to right (1-4): MW ladder, K562 parental, K562 Her2t, K562 ErbB2 (Her2).
  • Her2t is an effective selection marker in concert with EGFRt in central memory T cells (Tcm).
  • Tcm central memory T cells
  • CD 8 Tcm transduced with CD19CAR-T2A-Her2, CD20CAR-T2A-EGFRt, or both selected using biotinylated Herceptin or Erbitux and anti-biotin microbeads.
  • CD 8 Tcm transduced with CD 19CAR-T2A-Her2t and CD20CAR-T2A-EGFRt (Both) can be sequentially purified allowing for a dual-specific T cell for CAR therapy.
  • the fifth panel goes with the dual purified Tcm histogram (Both).
  • the top histogram shows Herceptin SAVE staining (Her2t+) and the bottom histogram shows Erbitux SA-PE staining (EGFRt+) for the dual purified Tcm.
  • Panel C Western blot analysis using a CD3 ⁇ specific antibody on cell lysates of Her2t or EGFRt purified CD8 Tcm.
  • FIG. 4 Her2t and Her2t/EGFRt transduced cells maintain effector phenotype and target specificity.
  • CD8 Tcm were co-cultured with K562 target cells at a 50: 1, 25: 1, 12.5: 1 or 6.25: 1 ratio.
  • CD 19CAR-T2A-Her2t and CD19CAR-T2A- EGFRt CD8 Tcm demonstrate similar lytic capacity.
  • CD 8 Tcm were co-cultured with K562 target cells at a 2: 1 T cell-to-target ratio for 24 hours and then supernatant was analyzed for the presence of effector cytokines.
  • CD19CAR- T2A-Her2t transduced CD8 Tcm produced a more diverse repertoire and higher levels of effector cytokines relative to CD19CAR-T2A-EGFRt transduced CD8 Tcm.
  • the panels are the same as A and B (Left to right: K562 parental, K562 CD 19, K562 CD20 and K562 CD19/CD20). Similar results were seen for CD4 Tcm (data not shown).
  • CD8 Tcm purified by Her2t (CD 19CAR-Her2t) produce significantly higher IL2, IFNy and TNFa effector cytokine levels when co-cultured with CD 19 expressing K562 (above) as compared to CD 19C AR-EGFRt. Student's t test p > 0.05.
  • FIG. 5 Use of Her2t as a marker for in vivo detection and fluorescent staining of engineered cells.
  • CD 19C AR-T2A-Her2t or CD19CAR- T2A-EGFRt-expressing CD4 and CD8 Tcm (10 7 ) were injected intravenously into NOD/scid IL-2RyC null mice alongside a subcutaneous injection of 5 x 10 6 NS0-IL15 cells to provide systemic supply of human IL-15. Bone marrow was harvested 14 days post injection and cell suspensions were analyzed by flow cytometry.
  • Panel B three panels showing cells gated for viable (93.6% lymphocytes), single (98.8%), and alive cells (99.9%).
  • CD 8 and CD45 staining of left to right (Mock, CD 19CAR-T2A-Her2t, CD 19CAR-T2A-EGFRt Tcm). At least lxl 0 7 cells were recorded inside of the viable, single cell and alive gates. So although the CD45+ cells represent around 1% of the population, it is equivalent to lxlO 5 cells. The remaining cells are mouse bone marrow cells.
  • Human CD45+ cells were co- stained with biotinylated Herceptin or Erbitux and SA-APC. Her2t- or EGFRt-expressing Tcm from bone marrow were identified.
  • TM-LCL parental, Her2(ErbB2) or Her2t expressing cells were adhered to slides using poly-L-lysine and then stained using biotinylated Herceptin and SA-AF647. Staining was only present for cells expressing Her2 or Her2t when stained with biotinylated Herceptin and SA-AF647.
  • FIG. 6 Multisort purification of Her2t and EGFRt positive T cells.
  • H9 cells (5xl0 6 parental, Her2t + , EGFRt + , or Her2t + /EGFRt + ) were mixed together and then subjected to purification. The cells were initially purified based on biotinylated Herceptin and anti-biotin multisort beads. The multisort beads were then removed and the positive fraction subsequently subjected to purification based on Erbitux-APC and anti-APC microbeads. The final positive fraction was dual positive for Her2t and EGFRt.
  • FIG. 7 Three variants of Her2t (CD28hinge, IgG4hinge or Her2tG) were designed to enhance binding to the antibody Herceptin. Shown is a general schematic indicating where the new sequences were inserted into Her2t.
  • FIG. 8 Her2tG displays enhanced binding to Herceptin.
  • H9 cells were transduced with lentivirus at an MOI of 1 with Her2t or Her2tG.
  • Transduced cells were then purified by biotinylated Herceptin and anti-biotin microbeads according to the manufacturers' protocol. The purified populations were later stained for Her2t or Her2tG using biotinylated Herceptin and streptavidin-PE. Histograms display greater binding to Her2tG.
  • Her2tG displays the greatest ability to bind Herceptin.
  • H9 cells were transduced with lentivirus at 0.05, 0.1, 0.25, 0.5, 1 and 3ul (left to right) and then analyzed for Herceptin binding five days later.
  • the Her2t variant Her2t(CD28hinge) was able to bind Herceptin at levels similar to the original Her2t (Her2t staining not shown but based on prior experience).
  • Her2t(IgG4 hinge) enhanced Herceptin binding relative to Her2t or Her2t(CD28hinge), while the Her2tG variant had the greatest capacity to bind Herceptin and stain transduced H9 cells.
  • Antigen refers to a molecule that provokes an immune response. This immune response can involve either antibody production, or the activation of specific immunologically-competent cells, or both. It is readily apparent that an antigen can be generated, synthesized, produced recombinantly or can be derived from a biological sample.
  • a biological sample can include, but is not limited to a tissue sample, a tumor sample, a cell or a biological fluid, such as, for example, blood, plasma, and ascites fluid.
  • Anti-tumor effect refers to a biological effect, which can be manifested by a decrease in tumor volume, a decrease in the number of tumor cells, a decrease in the number of metastases, an increase in life expectancy, or a decrease of various physiological symptoms associated with the cancerous condition.
  • An "anti-tumor effect” can also be manifested by a decrease in recurrence or an increase in the time before recurrence.
  • a method of treating a patient comprising administering an effective amount of a composition, wherein the composition comprises cells, wherein the cells of the composition express a chimeric antigen receptor that comprises an antigen binding domain that binds to the tumor antigen expressed on the cancer cell and a genetic tag.
  • the composition has an anti-tumor effect.
  • Chimeric receptor refers to a synthetically designed receptor comprising a ligand binding domain of an antibody or other protein sequence that binds to a molecule associated with the disease or disorder and is linked via a spacer domain to one or more intracellular signaling domains of a T cell or other receptors, such as a costimulatory domain.
  • Chimeric receptor can also be referred to as artificial T cell receptors, chimeric T cell receptors, chimeric immunoreceptors, and chimeric antigen receptors (CARs). These CARs are engineered receptors that can graft an arbitrary specificity onto an immune receptor cell.
  • Chimeric antigen receptors or "CARs" are referred to by some investigators to include the antibody or antibody fragment, the spacer, signaling domain, and transmembrane region.
  • the components of the CAR are described in some contexts herein as independent elements.
  • the variation of the different elements of the CAR can, for example, lead to stronger binding affinity for a ⁇ specific epitope.
  • Co-stimulatory domain refers to a signaling moiety that provides to T cells a signal which, in addition to the primary signal provided by for instance the CD3 zeta chain of the TCR/CD3 complex, mediates a T cell response, including, but not limited to, activation, proliferation, differentiation, cytokine secretion, and the like.
  • a co-stimulatory domain can include all or a portion of, but is not limited to, CD27, CD28, 4-1BB, OX40, CD30, CD40, ICOS, lymphocyte function-associated antigen-1 (LFA- 1), CD2, CD7, LIGHT, NKG2C, B7-H3, and/or a ligand that specifically binds with CD83.
  • the co-stimulatory domain is an intracellular signaling domain that interacts with other intracellular mediators to mediate a cell response including activation, proliferation, differentiation and cytokine secretion, and the like.
  • the chimeric antigen receptor comprises a co-stimulatory domain.
  • Coding for refers to the property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other macromolecules such as a defined sequence of amino acids. Coding for can be used interchangeably with the term, "encoding.” Thus, a gene codes for a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system.
  • a “nucleic acid sequence coding for a polypeptide” includes all nucleotide sequences that are degenerate versions of each other and that code for the same amino acid sequence.
  • CTL Cytotoxic T lymphocyte
  • T M cells memory T cells
  • Central memory T cell refers to an antigen experienced CTL that expresses CD62L or CCR-7 and CD45RO on the surface thereof, and does not express or has decreased expression of CD45RA as compared to naive cells.
  • central memory cells are positive for expression of CD62L, CCR7, CD28, CD 127, CD45RO, and/or CD95, and/or have decreased expression of CD54RA as compared to naive cells.
  • a host cell is provided wherein the host cell is antigen specific.
  • the cell is a central memory T cell.
  • Effective memory T cell refers to an antigen experienced T cell that does not express or has decreased expression of CD62L on the surface thereof as compared to central memory cells, and does not express or has decreased expression of CD45RA as compared to naive cell.
  • effector memory cells are negative for expression of CD62L and CCR7, compared to naive cells or central memory cells, and have variable expression of CD28 and CD45RA.
  • a host cell is provided wherein the host cell is antigen specific.
  • the cell is an effector memory T cell.
  • Ne ' ive T cells refers to a non-antigen experienced T lymphocyte that expresses CD62L and CD45RA, and does not express CD45RO- as compared to central or effector memory cells.
  • na ' ive CD8+ T lymphocytes are characterized by the expression of phenotypic markers of na ' ive T cells including CD62L, CCR7, CD28, CD127, and/or CD45RA.
  • a host cell is provided wherein the host cell is antigen specific.
  • the cell is a naive T cell.
  • T E T cells refers to an antigen experienced cytotoxic T lymphocyte cells that do not express or have decreased expression of CD62L, CCR7, and/or CD28, and are positive for granzyme B and/or perforin as compared to central memory or na ' ive T cells.
  • a host cell is provided wherein the host cell is antigen specific.
  • the cell is an effector T cell.
  • T cell precursors refers to lymphoid precursor cells that can migrate to the thymus and become T cell precursors, which do not express a T cell receptor. All T cells originate from hematopoietic stem cells in the bone marrow. Hematopoietic progenitors (lymphoid progenitor cells) from hematopoietic stem cells populate the thymus and expand by cell division to generate a large population of immature thymocytes. The earliest thymocytes express neither CD4 nor CD8, and are therefore classed as double-negative (CD4 CD8 ) cells.
  • CD4 CD8 double-negative
  • the double negative (DN) stage of the precursor T cell is focused on producing a functional ⁇ -chain whereas the double positive (DP) stage is focused on producing a functional a-chain, ultimately producing a functional ⁇ T cell receptor.
  • the T cell expresses an invariant a-chain but rearranges the ⁇ -chain locus. If the rearranged ⁇ - chain successfully pairs with the invariant a-chain, signals are produced which cease rearrangement of the ⁇ -chain (and silence the alternate allele) and result in proliferation of the cell.
  • these signals require this pre-TCR at the cell surface, they are dependent on ligand binding to the pre-TCR.
  • These thymocytes will then express both CD4 and CD8 and progresses to the double positive (DP) stage where selection of the a-chain takes place. If a rearranged ⁇ -chain does not lead to any signaling (e.g. as a result of an inability to pair with the invariant a-chain), the cell may die by neglect (lack of signaling).
  • Hematopoietic stem cells are precursor cells that can give rise to myeloid cells such as, for example, macrophages, monocytes, macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes/platelets, dendritic cells and lymphoid lineages (such as, for example, T-cells, B-cells, NK-cells).
  • HSCs have a heterogeneous population in which three classes of stem cells exist, which are distinguished by their ratio of lymphoid to myeloid progeny in the blood (L/M).
  • Enriched and “depleted” as used herein to describe amounts of cell types in a mixture refers to the subjecting of the mixture of the cells to a process or step which results in an increase in the number of the "enriched” type and a decrease in the number of the "depleted” cells.
  • a mixture or composition can contain 60, 70, 80, 90, 95, or 99 percent or more (in number or count) of the "enriched” cells, including any integer between any two endpoints of any of the listed values and 40, 30, 20, 10, 5 or 1 percent or less (in number or count) of the "depleted” cells, including any integer between any two endpoints of any of the listed values.
  • Epitope refers to a part of an antigen or molecule that is recognized by the immune system including antibodies, T cells, and/ or B cells. Epitopes usually have at least 7 amino acids and can be linear or conformational.
  • Her2 or "ERBB2” refers to a membrane bound protein kinase receptor that needs a co-receptor for ligand binding.
  • An exemplary polypeptide reference sequence for Her2 is found at Uniprot record P04626 and SEQ ID NO: 23. (Table 8) The full length reference sequence has 1255 amino acids including 1-22 amino acid signal sequence, 23-652 amino acid extracellular domain, 653-675 amino acid transmembrane domain, and 676-1255 amino acid cytoplasmic domain as shown in Table 8. The full length mature polypeptide sequence has 1233 amino acids as the leader sequence is not included in the mature polypeptide. A number of naturally occurring variants and isoforms are known.
  • a nucleic reference sequence is found at Genbank X03363/gI 31197.
  • the extracellular domain has 4 regions that correspond to: Domain I amino acids 23-217; domain II amino acids 218 to 341; domain III amino acids 342 to 510; and Domain IV amino acids 511 to 562 of SEQ ID NO: 23.
  • Her2t refers to a fragment of the sequence of Her2, and is useful as a genetic tag for transgene expression.
  • Her2t comprises domain IV of the extracellular domain of Her2 and excludes full length Her2.
  • Her2t specifically binds to an antibody specific for Domain IV of Her2.
  • Her2t comprises amino acids 511 to 562 or 563-652 of SEQ ID NO: 23.
  • isolated is used to describe the various polypeptides disclosed herein, and means polypeptide or nucleic acid that has been identified and separated and/or recovered from a component of its natural environment.
  • the isolated polypeptide or nucleic acid is free of association with all components with which it is naturally associated.
  • Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide or nucleic acid, and can include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes.
  • Intracellular signaling domain refers to all or a portion of one or more domains of a molecule (here the chimeric receptor molecule) that provides for activation of a lymphocyte. Intracellular domains of such molecules mediate a signal by interacting with cellular mediators to result in proliferation, differentiation, activation and other effector functions. In some alternatives, such molecules include all or portions of CD28, CD3, and/or 4-1BB, or combinations thereof.
  • Ligand refers to a substance that binds specifically to another substance to form a complex.
  • ligands include epitopes on antigens, molecules that bind to receptors, substrates, inhibitors, hormones, and activators.
  • Ligand binding domain refers to a substance or portion of a substance that binds to a ligand. Examples of ligand binding domains include antigen binding portions of antibodies, extracellular domains of receptors, and active sites of enzymes.
  • operably linked refers to functional linkage between a regulatory sequence and a heterologous nucleic acid sequence resulting in expression of the latter.
  • a first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence.
  • a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence.
  • operably linked DNA sequences are contiguous and, where necessary, it is to join two protein coding regions, in the same reading frame.
  • Percent (%) amino acid sequence identity is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software.
  • a % amino acid sequence identity value is determined by dividing (a) the number of matching identical amino acid residues between each or all of the polypeptide amino acid sequence of the reference Her2 sequence provided in SEQ ID NO: 15 or amino acids 563-652 of SEQ ID NO: 23 and the comparison amino acid sequence of interest as determined by WU-BLAST-2 by (b) the total number of amino acid residues of the polypeptide of interest.
  • Geneetic tag variant polynucleotide refers to a polypeptide-encoding nucleic acid molecule as defined below having at least about 80% nucleic acid sequence identity with the polynucleotide acid sequence shown in SEQ ID NO: 15 or nucleotides or a specifically derived fragment thereof.
  • a variant of polynucleotide or fragment thereof will have at least about 80%> nucleic acid sequence identity, more preferably at least about 81% nucleic acid sequence identity, more preferably at least about 82% nucleic acid sequence identity, more preferably at least about 83% nucleic acid sequence identity, more preferably at least about 84% nucleic acid sequence identity, more preferably at least about 85% nucleic acid sequence identity, more preferably at least about 86%) nucleic acid sequence identity, more preferably at least about 87% nucleic acid sequence identity, more preferably at least about 88% nucleic acid sequence identity, more preferably at least about 89% nucleic acid sequence identity, more preferably at least about 90%) nucleic acid sequence identity, more preferably at least about 91% nucleic acid sequence identity, more preferably at least about 92% nucleic acid sequence identity, more preferably at least about 93% nucleic acid sequence identity, more preferably at least about 94%) nucleic acid sequence identity, more preferably at least about 95% nucle
  • Variants do not encompass the native nucleotide sequence.
  • not substantially found when used in reference the presence of a tumor antigen or other molecules on normal cells refers to the percentage of a normal cell type that has the antigen or molecule, and/or the density of the antigen on the cells. In some alternatives, not substantially found means that the antigen or molecule is found on less than 50% of normal cell type and/or at a 50% less density as compared to the amount of cells or antigen found on a tumor cell or other diseased cell.
  • T cells or "T lymphocytes” as used herein can be from any mammalian, preferably primate, species, including monkeys, dogs, and humans.
  • the T cells are allogeneic (from the same species but different donor) as the recipient subject; in some alternatives, the T cells are autologous (the donor and the recipient are the same); in some alternatives, the T cells arc syngeneic (the donor and the recipients are different but are identical twins).
  • Vector or "construct” is a nucleic acid used to introduce heterologous nucleic acids into a cell that has regulatory elements to provide expression of the heterologous nucleic acids in the cell.
  • Vectors include but are not limited to plasmid, minicircles, yeast, and viral genomes.
  • This disclosure provides for a genetic tag polypeptide or variant thereof and a nucleic acid coding for the genetic tag useful to provide a selection marker and/or an identification marker for transgene expressing cells.
  • One aspect of the disclosure provides a genetic tag for transgene expression that provides stable expression of the transgene expression in cells.
  • the genetic tag provides for selection of transduced cells that express the transgene at levels comparable to endogenous genes.
  • the genetic tag is expressed on the cell surface, has decreased immunogenicity, does not substantially increase the genetic payload in a vector, and/or provides for transgene expression in a variety of cells.
  • the genetic tag is a fragment of Her2 designated as Her2t that at least includes an epitope recognized by an anti-Her2 antibody.
  • the antibody specifically binds to Domain IV of Her2.
  • the antibody specifically binds to Domain IV of Her2 and does not bind to epitopes in domains I, II, and/or III of Her2.
  • the anti-Her2 antibody is an antibody therapeutically useful for treating cancer.
  • the epitope is recognized by trastuzumab (Herceptin).
  • the epitope is recognized by trastuzumab and/or antibodies that compete for binding with trastuzumab but no other anti- Her2 antibodies that bind for example, to epitopes in domains I, II, and/or III of Her2.
  • the epitope includes amino acids as determined by the crystal structure of Her2 in complex with Herceptin Fab (Cho et al., Nature (2003) 421 :756). The interaction between Her2 and Herceptin occurs between three loop regions (two electrostatic and one hydrophobic) in Domain IV.
  • loop 1 electrostatic
  • loop 2 hydrophobic
  • DPPF including Asp 592 and Phe 595
  • loop 3 electrostatic
  • amino acid sequence 616-625 FPDEEGACOP including Gin 624
  • a fragment of Her2 contains at least these amino acid residues and is further selected for binding to trastuzumab or an antibody that competes for binding with trastuzumab when expressed on a cell surface. While not meant to limit the scope of the disclosure, it is believed that a Her2t fragment containing at least amino acids 563-652 includes an epitope that can bind trastuzumab as a smaller epitope containing amino acids 578 to 652 did not bind to trastuzumab.
  • the Her2t fragment comprises the amino acids 563-652 of Her2t. In some alternatives, the Her2t fragment comprises the amino acid sequences 580-584 of Her2t, amino acid sequences 592-595 of Her2t and amino acid sequences 616-625 of Her2t.
  • a fragment of Her2 comprises, consists essentially of, or consists of amino acids 511-652 (Domain IV) or 563-652 as shown in Table 6 (SEQ ID NO: 18).
  • a variant of the Her2 fragment has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the sequence of SEQ ID NO: 18 or a percentage sequence identity that is between a range defined by any two of the aforementioned percentages, and when expressed on the cell surface binds to trastuzumab.
  • the variant fragment has at least 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid substitutions, preferably conservative amino acid substitutions.
  • the variant fragment does not include amino acid substitution in the residues involved in binding to trastuzumab as described herein.
  • the fragment includes residues in Domain IV of Her2 and excludes one or more other domains of Her2 including domain 1, domain II, domain III, and/or intracellular domains.
  • the genetic tag generates little or no immune response.
  • a genetic tag is selected from endogenously occurring proteins in order to take advantage of the subject's tolerance to endogenous proteins.
  • the genetic tag is analyzed with software for predicting antigenic epitopes such as MHC-I antigenic peptide processing prediction algorithm.
  • a sequence: MLLLVTSLLLCELPHPAFLLIPCHPECQPQNGSVT (SEQ ID NO: 16) is analyzed for antigenic determinants.
  • the nucleic acid sequence of the genetic tag is derived from and/or modified from the germ line sequence for incorporation in an artificial or synthetic transgene construct.
  • a genetic tag further includes a transmembrane domain.
  • the transmembrane domain can be derived either from a natural or a synthetic source. When the source is natural, the domain can be derived from any membrane -bound or transmembrane protein. Transmembrane regions comprise at least the transmembrane region(s) of) the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3, CD45, CD4, CD8, CD9, CD16, CD22; CD33, CD37, CD64, CD80, CD86, CD134, CD137 and/or CD154. In a specific alternative, the transmembrane domain comprises the amino acid sequence of the Her2 transmembrane domain as shown in Table 6 (e.g. amino acids 653-675 (SEQ ID NO: 20). A representative polynucleotide sequence coding for the Her2 transmembrane domain (SEQ ID NO: 19) is shown in Table 6.
  • synthetic or variant transmembrane domains comprise predominantly hydrophobic residues, such as leucine and valine.
  • a transmembrane domain can have at least 80%, 85%, 90%, 95%, or 100% amino acid sequence identity with a transmembrane domain as shown in Table 6 or percentage sequence identity that is between a range defined by any two of the aforementioned percentages.
  • Variant transmembrane domains preferably have a hydrophobic score of at least 50 as calculated by Kyte Doolittle.
  • a genetic tag includes a peptide that enhances surface expression of the genetic tag.
  • peptides include, for example, including the granulocyte macrophage stimulating factor signal sequence, endogenous Her2 leader peptide (aa 1-22), type I signal peptides, IgGK signal peptide, and/or CD8 leader sequence.
  • the leader sequence has a sequence of SEQ ID NO: 17.
  • a genetic tag comprises a fragment of Her2 that binds trastuzumab, and a transmembrane domain as exemplified by SEQ ID NO: 20.
  • a genetic tag comprises a peptide that enhances surface expression, a fragment of Her2 that binds trastuzumab, and a transmembrane domain as exemplified by SEQ ID NO: 15.
  • a variant of the genetic tag has 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the sequence of SEQ ID NO: 16 or SEQ ID NO:20 or a percentage sequence identity that is between a range defined by any two of the aforementioned percentages, and when expressed on the cell surface binds to trastuzumab.
  • the variant fragment has at least 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid substitutions, preferably conservative amino acid substitutions.
  • the variant fragment does not include amino acid substitution in the residues involved in binding to trastuzumab.
  • a linker sequence can precede the genetic tag sequence and/or separate one or more functional domains (e.g. peptide to enhance surface expression, genetic tag, transmembrane domain) of the genetic tag.
  • Linker sequences are optionally cleavable, for example, T2A sequences (as shown in Table 1) or IRES sequences.
  • Cleavable linker sequences are typically placed to precede the genetic tag sequence in a nucleic acid construct.
  • Other linker sequences are typically short peptides, of about 2 to 15 amino acids and are located between functional domains of the genetic tag including the peptide to enhance surface expression, genetic tag, and transmembrane domain.
  • the linkers are between 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids and are located between functional domains of the genetic tag including the peptide to enhance surface expression, genetic tag, and transmembrane domain.
  • the linker is a cleavable linker.
  • the linker is a cleavable T2A sequence.
  • the linker comprises IRES sequences.
  • the system further comprises one or more additional genetic tags.
  • the additional genetic tag sequence is a fragment of an epidermal growth factor receptor (EGFRt) sequence.
  • EGFRt epidermal growth factor receptor
  • Table 7 An example of such a sequence is provided in Table 7.
  • a genetic tag sequence has a functional characteristic that allows for selection of transduced cells and/or detection of transduced cells.
  • the genetic tag sequence is compatible with transduction of human lymphocytes.
  • an additional genetic tag is a positive selectable marker.
  • a positive selectable genetic tag can be a gene, which upon being introduced into the host cell, expresses a dominant phenotype permitting positive selection of cells carrying the gene. Genes of this type are known in the art, and include, inter alia, hygromycin-B phosphotransferase gene (hph) which confers resistance to hygromycin B, the amino glycoside phosphotransferase gene (neo or aph) from Tn5 which codes for resistance to the antibiotic G418, the dihydro folate reductase (DHFR) gene which provides resistance to methotrexate, DHFR dm, the pac gene that provides resistance to puromycin, Sh ble gene which inactivates zeocin, the adenosine deaminase gene (ADA), and the multi-drug resistance (MDR) gene. Transduced cells cultured in the presence of these agents will survive and be selected. In some aspects of the h
  • a first nucleic acid further comprises a polynucleotide coding for a genetic tag sequence.
  • the genetic tag sequence is a Her2t sequence.
  • An exemplary polynucleotide and amino acid for the Her2t sequences is shown in Table 6 and provided by SEQ ID NO: 14 and SEQ ID NO: 15, respectively.
  • the genetic tag sequence is an epidermal growth factor receptor fragment (EGFRt) as shown in Table 7.
  • EGFRt epidermal growth factor receptor fragment
  • An exemplary polynucleotide for the truncated epidermal growth factor receptor is SEQ ID NO: 22.
  • a polynucleotide coding for genetic tag can be readily prepared by synthetic or recombinant methods from the amino acid sequence.
  • a polynucleotide coding for a genetic tag sequence is operably linked to a polynucleotide coding for a linker sequence.
  • the polynucleotide coding for a genetic tag sequence can also have one or more restriction enzyme sites at the 5' and/or 3' ends of the coding sequence in order to provide for easy excision and replacement of the polynucleotide coding for a tag sequence with another polynucleotide coding for a different genetic tag sequence.
  • the polynucleotide coding for a marker sequence is codon optimized for expression in mammalian cells, preferably humans.
  • two or more genetic tag sequences can be employed.
  • a first genetic tag sequence is operably linked to a first chimeric antigen receptor and provides for an indication that the transduced cell is expressing the first CAR.
  • a second genetic tag sequence is operably linked to a second and different CAR and provides an indication that the transduced cell is expressing the second CAR.
  • Another aspect of the disclosure includes nucleic acid constructs and variants thereof coding for the genetic tags as described herein.
  • a nucleic acid codes for an amino acid sequence of a fragment Her2 or a variant thereof.
  • a nucleic acid codes for a polypeptide having an amino acid sequence of SEQ ID NO: 18.
  • a nucleic acid codes for a polypeptide having an amino acid sequence of SEQ ID NO: 15.
  • the genetic tag sequence is an epidermal growth factor receptor fragment (EGFRt) as shown in Table 7.
  • An exemplary polynucleotide for the truncated epidermal growth factor receptor is SEQ ID NO: 21.
  • Nucleic acids include nucleic acid sequences that are codon optimized for expression in humans, degenerate sequences, and variant sequences.
  • a vector comprises a nucleic acid coding for a genetic tag.
  • a nucleic acid coding for a genetic tag can be packaged in a vector as a separate construct or linked to a nucleic acid coding for a transgene.
  • a nucleic acid coding for a genetic tag is packaged in a vector as a separate construct or linked to a nucleic acid coding for a transgene
  • the vector is a dual packaged or single (all in one) viral vector.
  • the vectors can include a combination of viral vectors and plasmid vectors.
  • Other viral vectors include foamy virus, adenoviral vectors, retroviral vectors, and lentiviral vectors.
  • the vector is a lentiviral vector.
  • a plasmid vector or a viral vector comprises a nucleic acid comprising a polynucleotide coding for a genetic tag.
  • the genetic tag comprises a polynucleotide coding for Her2t, and further comprises a promoter, a polynucleotide coding for a peptide to enhance surface expression and/or a polynucleotide coding for a transmembrane domain.
  • the first nucleic acid codes for a polypeptide having a sequence of SEQ ID NO: 18 or SEQ ID NO: 20 or SEQ ID NO: 15 or variant thereof operably linked to a promoter.
  • a plasmid or viral vector comprises a promoter operably linked to a polynucleotide coding for a chimeric antigen receptor operably linked to a polynucleotide coding for a genetic tag.
  • the chimeric antigen receptor is directed to CD 19 or CD20 and the genetic tag comprises Her2t fragment.
  • the polynucleotide coding for the CAR is operably linked to the genetic tag with a self-cleavable linker.
  • a plasmid or viral vector comprises a promoter operably linked to a polynucleotide coding for a CD 19 chimeric antigen receptor operably linked to a polynucleotide coding for Her2t or EGFRt.
  • a plasmid or viral vector comprises a promoter operably linked to a polynucleotide coding for a CD20 chimeric antigen receptor operably linked to a polynucleotide coding for Her2t or EGFRt.
  • Each element of the nucleic acid can be separated from one another with a linker sequence, preferably, a self-cleaving linker such as a T2A self-cleaving sequence.
  • a linker sequence preferably, a self-cleaving linker such as a T2A self-cleaving sequence.
  • the heterogeneous (heterogeneous to the vector, e,g, lentiviral vector) nucleic acid sequence is limited by the amount of additional genetic components that can be packaged in the vector.
  • a construct contains at least two genes heterogenous to the viral vector.
  • the construct contains no more than 4 genes heterogenous to the viral vector. The number of genes heterogenous to the viral vector that can be packaged in the vector can be determined by detecting the expression of one or more transgenes, and selecting vector constructs that provide for transduction of at least 10% of the cells and/or detectable expression levels of the transgene in at least 10% of the cells.
  • a lentivirus is a dual packaged virus.
  • a dual packaged virus contains at least one nucleic acid comprising a polynucleotide coding for a chimeric antigen receptor and a first genetic tag.
  • the nucleic acid further comprises a polynucleotide coding for a cytokine, and/or a chemokine receptor.
  • a dual packaged virus contains at least one nucleic acid comprising a polynucleotide coding for a chimeric antigen receptor and a second genetic tag.
  • the nucleic acid further comprises a polynucleotide coding for a cytokine, and/or a chemokine receptor.
  • each construct can be packaged in a separate viral vector and the viral vectors can be mixed together for transduction in a cell population.
  • the first and second genetic tags are different from one another.
  • the dual packaged virus provides for expression of at least two different transgenes, (e.g. CAR constructs) in a single cell type. Using different genetic tags provides for selection of dual transduced cells.
  • a plasmid or viral vector comprises a promoter operably linked to a polynucleotide coding for a CD 19 chimeric antigen receptor operably linked to a polynucleotide coding for Her2t.
  • the plasmid or viral vector further comprises a promoter operably linked to a polynucleotide coding for a CD20 chimeric antigen receptor operably linked to a polynucleotide coding for EGFRt.
  • the vector is a minicircle.
  • Minicircles are episomal DNA vectors that are produced as circular expression cassettes devoid of any bacterial plasmid DNA backbone. Their smaller molecular size enables more efficient trans fections and offers sustained expression over a period of weeks as compared to standard plasmid vectors that only work for a few days.
  • a minicircle comprises a promoter linked to a polynucleotide coding for a chimeric antigen receptor operably linked to a genetic tag.
  • One or more minicircles can be employed.
  • a minicircle comprises a promoter linked to a polynucleotide coding for a chimeric antigen receptor and first genetic tag
  • another minicircle comprises a promoter linked to a polynucleotide coding for a chimeric antigen receptor and a second and different genetic tag.
  • each element of the constructs is separated by a nucleic acid, such as one coding for a self- cleaving T2A sequence.
  • each minicircle differs from one another in the chimeric antigen receptor including but not limited to the spacer length and sequence, the intracellular signaling domain, and/or the genetic tag sequence.
  • the vector is a PiggyBac transposon.
  • the PiggyBac (PB) transposon is a mobile genetic element that efficiently transposes between vectors and chromosomes via a "cut and paste" mechanism.
  • the PB transposase recognizes transposon-specific inverted terminal repeat sequences (ITRs) located on both ends of the transposon vector and efficiently moves the contents from the original sites and efficiently integrates them into TTAA chromosomal sites.
  • ITRs inverted terminal repeat sequences
  • a PB contains a promoter linked to a polynucleotide coding for a chimeric antigen receptor operably linked to a genetic tag.
  • One or more PB transposons can be employed.
  • a PB comprises a promoter linked to a polynucleotide coding for a chimeric antigen receptor and a first genetic tag
  • another PB comprises a promoter linked to a polynucleotide coding for a chimeric antigen receptor
  • a second and different genetic tag Each element of the constructs is separated by a nucleic acid, such as that coding for a self-cleaving T2A sequence.
  • each PB differs from one another in the chimeric antigen receptor including but not limited to the spacer length and sequence, the intracellular signaling domain, and/or the genetic tag sequence.
  • a first nucleic acid comprises a first promoter operably linked to a polynucleotide coding for chimeric antigen receptor comprising a ligand binding domain, wherein the ligand binding domain binds to a ligand, wherein the ligand is a tumor specific molecule, viral molecule, or any other molecule expressed on a target cell population that is suitable to mediate recognition and elimination by a lymphocyte; a polynucleotide coding for a polypeptide spacer, wherein the spacer provides for increased T cell proliferation and/or cytokine production in response to the ligand as compared to a reference chimeric receptor; a polynucleotide coding for a transmembrane domain; and d) a polynucleotide coding for an intracellular signaling domain.
  • the first nucleic acid further comprises a genetic tag.
  • a second nucleic acid comprises a polynucleotide coding for a second and different chimeric antigen receptor.
  • the first and second chimeric antigen receptor can differ from one another in the ligand binding domain, the target antigen, an epitope of the target antigen, the spacer domain in length and sequence (short medium or long), and in the intracellular signaling domains.
  • the second nucleic acid further comprises a second and different genetic tag from that of the first nucleic acid.
  • the first and second nucleic acids can be separated by a genomic insulator nucleic acid such as the sea urchin insulator chromatin domain.
  • One or more of these vectors can be used in conjunction with one another to transduce target cells and provide for expression of a chimeric antigen receptor.
  • Transgenes can be used in conjunction with one another to transduce target cells and provide for expression of a chimeric antigen receptor.
  • Severeal transgenes are also aspects of the invention.
  • a system for expression of chimeric antigen receptor comprises: a first nucleic acid comprising a first promoter linked to a polynucleotide coding for a chimeric antigen receptor, the chimeric antigen receptor comprising a ligand binding domain, wherein the ligand binding domain binds to a ligand, wherein the ligand is a tumor specific molecule, viral molecule, or any other molecule expressed on a target cell population that is suitable to mediate recognition and elimination by a lymphocyte; a polynucleotide coding for a polypeptide spacer, wherein the spacer provides for increased T cell proliferation and/or cytokine production in response to the ligand as compared to a reference chimeric receptor; a polynucleotide coding for a transmembrane domain; and d) a polynucleotide coding for an intracellular signaling domain.
  • the chimeric receptor nucleic acid comprises a polynucleotide coding for a ligand binding domain.
  • the ligand binding domain specifically binds to a tumor or viral specific antigen.
  • a ligand binding domain includes without limitation, receptors or portions thereof, small peptides, peptidomimetics, substrates, cytokines, and the like.
  • the ligand binding domain is an antibody or fragment thereof. A nucleic acid sequence coding for an antibody or antibody fragment can readily be determined.
  • the polynucleotide codes for a single chain Fv that specifically binds CD 19.
  • the polynucleotide codes for a single chain Fv that specifically binds CD20, HER2, CE7, hB7H3, or EGFR.
  • the sequences of these antibodies are known to or can readily be determined by those of skill in the art.
  • Tumor antigens are proteins that are produced by tumor cells that elicit an immune response.
  • the selection of the ligand binding domain of the disclosure will depend on the type of cancer to be treated, and can target tumor antigens or other tumor cell surface molecules.
  • a tumor sample from a subject can be characterized for the presence of certain biomarkers or cell surface markers.
  • breast cancer cells from a subject can be positive or negative for each of Her2Neu, Estrogen receptor, and/or the Progesterone receptor.
  • a tumor antigen or cell surface molecule is selected that is found on the individual subject's tumor cells.
  • Tumor antigens and cell surface molecules are well known in the art and include, for example, carcinoembryonic antigen (CEA), prostate specific antigen, PSMA, Her2/neu, estrogen receptor, progesterone receptor, ephrinB2, CD 19, CD171, EGFR, CD20, CD22, CD23, CD 123, CS-1, CE7, hB7H3, ROR1, mesothelin, c-Met, GD-2, and/or MAGE A3 TCR.
  • a target molecule is a cell surface molecule that is found on tumor cells and is not substantially found on normal tissues, or restricted in its expression to non-vital normal tissues.
  • the target molecule on the tumor comprises one or more epitopes associated with a malignant tumor.
  • Malignant tumors express a number of proteins that can serve as target antigens for T cell receptor or chimeric receptor mediated recognition.
  • Other target molecules belong to the group of cell transformation-related molecules such as CD 19 or CD20.
  • the tumor antigen is selectively expressed or overexpressed on the tumor cells as compared to control cells of the same tissue type.
  • the tumor antigen is a cell surface polypeptide.
  • Antibodies that specifically bind a tumor cell surface molecule can be prepared using methods of obtaining monoclonal antibodies, methods of phage display, methods to generate human or humanized antibodies, or methods using a transgenic animal or plant engineered to produce human antibodies. Phage display libraries of partially or fully synthetic antibodies are available and can be screened for an antibody or fragment thereof that can bind to the target molecule. Phage display libraries of human antibodies are also available. In some alternatives, antibodies specifically bind to a tumor cell surface molecule and do not cross react with nonspecific components such as bovine serum albumin or other unrelated antigens.
  • amino acid sequence or polynucleotide sequence coding for the antibody can be isolated and/or determined.
  • phage display libraries of partially or fully synthetic antibodies are screened for an antibody or fragment thereof that can bind to a target molecule.
  • a number of different antibodies that bind to particular tumor cell surface molecules can be isolated and characterized.
  • the antibodies are characterized based on epitope specificity of the targeted molecule.
  • antibodies that bind to the same epitope can be selected based on the affinity of the antibody for that epitope.
  • an antibody has an affinity of at least 1 mM, and preferably ⁇ 50 nM.
  • an antibody is selected that has a higher affinity for the epitope as compared to other antibodies.
  • an antibody is selected that has at least a 2 fold, at least a 5 fold, at least a 10 fold, at least a 20 fold, at least a 30 fold, at least a 40 fold, or at least a 50 fold greater affinity than a reference antibody that binds to the same epitope.
  • an antibody is selected that has at least a 2 fold, at least a 5 fold, at least a 10 fold, at least a 20 fold, at least a 30 fold, at least a 40 fold, or at least a 50 fold greater affinity, than a reference antibody that binds to the same epitope or any value of greater affinity between any of the defined values listed.
  • target molecules are selected from CD 19, CD20, CD22, CD23, CE7, hB7H3, EGFR, CD 123, CS-1, ROR1, mesothelin, Her2, c-Met, PSMA, GD-2, and/or MAGE A3 TCR and combinations thereof.
  • the genetic tag comprises an epitope that does not bind to the scFv for Her2 used in the CAR construct.
  • the genetic tag comprises an epitope that does not bind to the scFv for EGFR used in the CAR construct.
  • the target antigen is CD 19.
  • a number of antibodies specific for CD 19 are known to those of skill in the art and can be readily characterized for sequence, epitope binding, and affinity.
  • the chimeric receptor construct includes a scFV sequence from FMC63 antibody.
  • the scFV is a human or humanized ScFv comprising a variable light chain comprising a CDRLl sequence of RASQDISKYLN (SEQ ID NO: 27), CDRL2 sequence of SRLHSGV (SEQ ID NO:28), and a CDRL3 sequence of GNTLPYTFG (SEQ ID NO: 29).
  • the scFV is a human or humanized ScFv comprising a variable heavy chain comprising CDRHl sequence of DYGVS (SEQ ID NO: 30), CDRH2 sequence of VIWGSETTYYNSALKS (SEQ ID NO: 31), and a CDRH3 sequence of YAMDY (SEQ ID NO: 32).
  • the disclosure also contemplates variable regions that have at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity to that of the scFv for FMC63 or a percentage sequence identity that is between a range defined by any two of the aforementioned percentages and that have at least the same affinity for CD 19.
  • CDR regions are found within antibody regions as numbered by Kabat as follows: for the light chain; CDRLl amino acids 24-34;CDRL2 amino acids 50-56; CDRL3 at amino acids 89-97; for the heavy chain at CDRHl at amino acids 31- 35; CDRH2 at amino acids 50-65; and for CDRH3 at amino acids 95-102. CDR regions in antibodies can be readily determined.
  • the target antigen is CD20.
  • a number of antibodies specific for CD20 are known to those of skill in the art and can be readily characterized for sequence, epitope binding, and affinity.
  • the chimeric receptor construct includes a scFV sequence as shown in Table 9.
  • the scFV is a human or humanized ScFv comprising a variable light chain comprising a CDRL1 sequence of RA S S S V N Y M D (SEQ ID NO: 33), CDRL2 sequence ofATSNLAS (SEQ ID NO: 34), and a CDRL3 sequence ofQQWSFNPP T (SEQ ID NO: 35).
  • the scFV is a human or humanized ScFv comprising a variable heavy chain comprising CDRHl sequence of S Y N M H (SEQ ID NO: 36), CDRH2 of A IYPGNGDTSYNQKFKG (SEQ ID NO: 37), and a CDRH3 sequence ofSNYYGSSYWFFDV (SEQ ID NO: 38).
  • the CDR sequences can readily be determined from the amino acid sequence of the scFv.
  • variable regions that have at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity to that of the scFv for CD20 or a percentage sequence identity that is between a range defined by any two of the aforementioned percentages and that have at least the same affinity for CD20.
  • a polynucleotide coding for a ligand binding domain is operably linked to a polynucleotide coding for a spacer region.
  • the polynucleotide coding for a ligand binding domain can also have one or more restriction enzyme sites at the 5' and/or 3' ends of the coding sequence in order to provide for easy excision and replacement of the polynucleotide with another polynucleotide coding for a ligand binding domain coding for a different antigen or that has different binding characteristics.
  • a restriction site Nhel
  • a 3' RsrII located within the hinge region allows sub-cloning of any desirable scFv into a chimeric receptor vector.
  • the polynucleotide is codon optimized for expression in mammalian cells. In some alternatives, the polynucleotide is codon optimized for expression in human cells.
  • the polynucleotide coding for a ligand binding domain is operably linked to a promoter.
  • a promoter is selected that provides for expression of the chimeric antigen receptor in a mammalian cell.
  • the promoter is an inducible promoter.
  • a specific alternative of a polynucleotide coding for a ligand binding domain is shown in Table 1 as the scFv from an antibody that specifically binds CD 19, such as FMC63.
  • a polynucleotide encoding for a flexible linker including the amino acids GSTSGSGKPGSGEGSTKG (SEQ ID NO: 39) separates the VH and VL chains in the scFV.
  • the amino acid sequence of the scFv including the linker is shown in Table 1.
  • SEQ ID NO: 2 Other CD19-targeting antibodies such as SJ25C1 and HD37 are known.
  • SJ25C1 Bejcek et al. Cancer Res 2005, PMID 7538901
  • HD37 Pezutto et al. JI 1987, PMID 2437199.
  • a specific alternative of a polynucleotide coding for a ligand binding domain is shown in Table 9 as the scFv from an antibody that specifically binds CD20.
  • a polynucleotide encoding for a flexible linker including the amino acids GSTSGSGKPGSGEGSTKG (SEQ ID NO: 39) separates the VH and VL chains in the scFV.
  • the amino acid sequence of the scFv is shown in Table 9 (SEQ ID NO: 25).
  • Other CD20- targeting antibodies such as 1F5 (Budde et al. 2013, PLOS One) are known.
  • the chimeric receptor nucleic acid comprises a polynucleotide coding for a spacer region.
  • a spacer region is found between the ligand binding domain and the transmembrane domain of the chimeric receptor.
  • a spacer region provides for flexibility of the ligand binding domain, allows for high expression levels in lymphocytes.
  • a CD19-specific chimeric receptor having a spacer domain of about 229 amino acids had less antitumor activity than a CD19-specific chimeric receptor with a short spacer region comprised of the modified IgG4 hinge only.
  • a spacer region has at least 10 to 229 amino acids, 10 to 200 amino acids, 10 to 175 amino acids, 10 to 150 amino acids, 10 to 125 amino acids, 10 to 100 amino acids, 10 to 75 amino acids, 10 to 50 amino acids, 10 to 40 amino acids, 10 to 30 amino acids, 10 to 20 amino acids, or 10 to 15 amino acids, or a length that is within a range defined by any two of the aforementioned amino acid lengths.
  • a spacer region has 12 amino acids or less but greater than 1 amino acid, 119 amino acids or less but greater than 1 amino acid, or 229 amino acids or less but greater than 1 amino acid.
  • the spacer region is derived from a hinge region of an immunoglobulin like molecule.
  • a spacer region comprises all or a portion of the hinge region from a human IgGl, human IgG2, a human IgG3, or a human IgG4, and can contain one or more amino acid substitutions. Exemplary sequences of the hinge regions are provided in Table 5.
  • a portion of the hinge region includes the upper hinge amino acids found between the variable heavy chain and the core, and the core hinge amino acids including a polyproline region.
  • hinge region sequences can be modified in one or more amino acids in order to avoid undesirable structural interactions such as dimerization.
  • the spacer region comprises a portion of a modified human hinge region from IgG4, for example, as shown in Table 1 or Table 5 (SEQ ID NO: 10).
  • a representative of a polynucleotide coding for a portion of a modified IgG4 hinge region is provided in Table 1. (SEQ ID NO: 1).
  • a hinge region can have at least about 90%, 92%, 95%, or 100% sequence identity with a hinge region amino acid sequence identified in Table 1 or Table 5.
  • a portion of a human hinge region from IgG4 has an amino acid substitution in the core amino acids from CPSP to CPPC.
  • all or a portion of the hinge region is combined with one or more domains of a constant region of an immunoglobulin.
  • a portion of a hinge region can be combined with all or a portion of a CH2 or CH3 domain or variant thereof.
  • the spacer region does not include the 47-48 amino acid hinge region sequence from CD8 alpha or the spacer region comprising an extracellular portion of the CD28 molecule.
  • a short spacer region has about 12 amino acids or less but greater than 1 amino acid and comprises all or a portion of a IgG4 hinge region sequence or variant thereof
  • an intermediate spacer region has about 119 amino acids or less but greater than 1 amino acid and comprises all or a portion of a IgG4 hinge region sequence and a CH3 region or variant thereof
  • a long spacer has about 229 amino acids or less but greater than 1 amino acid and comprises all or a portion of a IgG4 hinge region sequence, a CH2 region, and a CH3 region or variant thereof.
  • a polynucleotide coding for a spacer region can be readily prepared by synthetic or recombinant methods from the amino acid sequence.
  • a polynucleotide coding for a spacer region is operably linked to a polynucleotide coding for a transmembrane region.
  • the polynucleotide coding for the spacer region can also have one or more restriction enzyme sites at the 5' and/or 3' ends of the coding sequence in order to provide for easy excision and replacement of the polynucleotide with another polynucleotide coding for a different spacer region.
  • the polynucleotide coding for the spacer region is codon optimized for expression in mammalian cells. In some alternatives, the polynucleotide coding for the spacer region is codon optimized for expression in human cells.
  • the spacer region is selected from a hinge region sequence from IgGl, IgG2, IgG3, or IgG4 or portion thereof, a hinge region sequence from IgGl, IgG2, IgG3, or IgG4 in combination with all or a portion of a CH2 region or variant thereof, a hinge region sequence from IgGl, IgG2, IgG3, or IgG4 in combination with all or a portion of a CH3 region or variant thereof, and a hinge region sequence from IgGl, IgG2, IgG3, or IgG4 in combination with all or a portion of a CH2 region or variant thereof, and a CH3 region or variant thereof.
  • a short spacer region is a modified IgG4 hinge sequence (SEQ ID NO: 10) having 12 amino acids or less but greater than 1 amino acid
  • an intermediate sequence is a IgG4 hinge sequence with a CH3 sequence having 119 amino acids or less but greater than 1 amino acid
  • a IgG4 hinge sequence with a CH2 and CH3 region having 229 amino acids or less but greater than 1 amino acid.
  • a short spacer region has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acids or a size within a range defined by any two of the aforementioned amino acid lengths.
  • a medium spacer region has 13, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 or 119 amino acids or a size within a range defined by any two of the aforementioned amino acid lengths.
  • a spacer region has 120, 130, 140, 150, 160, 170, 180, 190, 200, 210 or 219 amino acids or a size within a range defined by any two of the aforementioned amino acid lengths.
  • the chimeric receptor nucleic acid comprises a polynucleotide coding for a transmembrane domain.
  • the transmembrane domain provides for anchoring of the chimeric receptor in the membrane.
  • the transmembrane domain of the chimeric antigen receptor is different than that of the genetic tag.
  • the transmembrane domain that naturally is associated with one of the domains in the chimeric receptor is used.
  • the transmembrane domain can be selected or modified by amino acid substitution to avoid binding of such domains to the transmembrane domains of the same or different surface membrane proteins to minimize interactions with other members of the receptor complex.
  • the transmembrane domain can be derived either from a natural or a synthetic source. When the source is natural, the domain can be derived from any membrane- bound or transmembrane protein. Transmembrane regions comprise at least the transmembrane region(s) of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3, CD45, CD4, CD8, CD9, CD16, CD22; CD33, CD37, CD64, CD80, CD86, CD134, CD137 and/or CD 154. In a specific alternative, the transmembrane domain comprises the amino acid sequence of the CD28 transmembrane domain as shown in Table 2. A representative polynucleotide sequence coding for the CD28 transmembrane domain is shown in Table 1 (within SEQ ID NO: 2).
  • a transmembrane domain can be synthetic or a variant of a naturally occurring transmembrane domain.
  • synthetic or variant transmembrane domains comprise predominantly hydrophobic residues such as leucine and valine.
  • a transmembrane domain can have at least 80%, 85%, 90%, 95%, or 100% amino acid sequence identity with a transmembrane domain as shown in Table 2 or Table 6 or a sequence identity that is a percentage within a range defined by any two of the aforementioned percentages.
  • Variant transmembrane domains preferably have a hydrophobic score of at least 50 as calculated by Kyte Doolittle.
  • a polynucleotide coding for a transmembrane domain can be readily prepared by synthetic or recombinant methods.
  • a polynucleotide coding for a transmembrane domain is operably linked to a polynucleotide coding for an intracellular signaling region.
  • the polynucleotide coding for a transmembrane domain can also have one or more restriction enzyme sites at the 5' and/or 3' ends of the coding sequence in order to provide for easy excision and replacement of the polynucleotide coding for a transmembrane domain with another polynucleotide coding for a different transmembrane domain.
  • the polynucleotide coding for a transmembrane domain is codon optimized for expression in mammalian cells, preferably human cells.
  • Intracellular signaling domain Intracellular signaling domain.
  • the chimeric receptor nucleic acid comprises a polynucleotide coding for an intracellular signaling domain.
  • the intracellular signaling domain provides for activation of one function of the transduced cell expressing the chimeric receptor upon binding to the ligand expressed on tumor cells.
  • the intracellular signaling domain contains one or more intracellular signaling domains.
  • the intracellular signaling domain is a portion of and/or a variant of an intracellular signaling domain that provides for activation of at least one function of the transduced cell.
  • intracellular signaling domains for use in a chimeric receptor of the disclosure include the cytoplasmic sequences of the CD3 zeta chain, and/or co- receptors that act in concert to initiate signal transduction following chimeric receptor engagement, as well as any derivative or variant of these sequences and any synthetic sequence that has the same functional capability.
  • T cell activation can be said to be mediated by two distinct classes of cytoplasmic signaling sequence: those that initiate antigen- dependent primary activation and provide a T cell receptor like signal (primary cytoplasmic signaling sequences) and those that act in an antigen-independent manner to provide a secondary or co-stimulatory signal (secondary cytoplasmic signaling sequences).
  • Primary cytoplasmic signaling sequences that act in a stimulatory manner can contain signaling motifs which are known as receptor tyrosine-based activation motifs or ITAMs.
  • ITAM containing primary cytoplasmic signaling sequences include those derived from CD3 zeta, FcR gamma, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, and/or CD66d.
  • the primary signaling intracellular domain can have at least 80%, 85%, 90%, or 95% sequence identity to CD3zeta having a sequence provided in Table 4 or a percentage sequence identity that is within a range defined by any two of the aforementioned percentages.
  • variants of CD3 zeta retain at least one, two, three or all IT AM regions as shown in Table 4.
  • the intracellular signaling domain of the chimeric receptor can be designed to comprise the CD3-zeta signaling domain by itself or combined with any other desired cytoplasmic domain(s).
  • the intracellular signaling domain of the chimeric receptor can comprise a CD3zeta chain and a costimulatory signaling region.
  • the co-stimulatory signaling region refers to a portion of the chimeric receptor comprising the intracellular domain of a costimulatory molecule.
  • a co-stimulatory molecule is a cell surface molecule other than an antigen receptor or their ligands that is required for a response of lymphocytes to an antigen. Examples of such molecules include CD27, CD28, 4- IBB (CD 137), OX40, CD30, CD40, lymphocyte function-associated antigen- 1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, zeta chain associated protein kinase (ZAP70), and/or a ligand that specifically binds with CD83.
  • the costimulatory signaling domain can have at least 80%, 85%, 90%, or 95% amino acid sequence identity to the intracellular domain of CD28 as shown in Table 2 or to 4- IBB having a sequence provided in Table 3 or any percent sequence identity that is within a range defined by any two of the aforementioned percentages.
  • a variant of the CD28 intracellular domain comprises an amino acid substitution at positions 186-187, wherein LL is substituted with GG.
  • the intracellular signaling sequences of the chimeric receptor can be linked to each other in a random or specified order.
  • a short oligo- or polypeptide linker preferably between 2 and 10 amino acids in length can form the linkage.
  • a short oligo- or polypeptide linker comprise 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids or a size that is within a range defined by any two of the aforementioned sizes.
  • the intracellular signaling domains comprises all or a portion of the signaling domain of CD3-zeta or variant thereof and all or a portion of the signaling domain of CD28 or a variant thereof.
  • the intracellular signaling domain comprises all or a portion of the signaling domain of CD3-zeta or variant thereof and all or a portion of the signaling domain of 4-lBB or variant thereof.
  • the intracellular signaling domain comprises all or a portion of the signaling domain of CD3-zeta or variant thereof, all or a portion of the signaling domain of CD28 or variant thereof, and all or a portion of the signaling domain of 4-1BB or variant thereof.
  • the amino acid sequence of the intracellular signaling domain comprising a variant of CD3zeta and a portion of the 4- IBB intracellular signaling domain is provided in Table 1.
  • a representative nucleic acid sequence is provided in Table 1 (within SEQ ID NO: 2).
  • a polynucleotide coding for an intracellular signaling domain comprises a 4- IBB intracellular domain linked to a portion of a CD3zeta domain.
  • a 4- IBB intracellular domain and a CD28 intracellular domain are linked to a portion of a CD3 zeta domain.
  • a polynucleotide coding for an intracellular signaling domain can be readily prepared by synthetic or recombinant methods from the amino acid sequence.
  • the polynucleotide coding for an intracellular signaling domain can also have one or more restriction enzyme sites at the 5' and/or 3' ends of the coding sequence in order to provide for easy excision and replacement of the polynucleotide coding for an intracellular signaling domain with another polynucleotide coding for a different intracellular signaling domain.
  • the polynucleotide coding for an intracellular signaling domain is codon optimized for expression in mammalian cells.
  • the polynucleotide coding for an intracellular signaling domain is codon optimized for expression in human cells.
  • a linker domain is provided for flexibility between domains in a CAR construct.
  • a linker (SEQ ID NO: 45) between Domain IV and the transmembrane domain of Her2t led to the construct Her2tG.
  • the linker is used to induce flexibility between protein domains.
  • the scFv of many CARs contain four consecutive G3S subunits placed between the Vh and VI domains of the CAR's scFv. This allows for flexibility in folding of the two scFv domains.
  • the rational of using two G3S linker subunits would suffice in being able to induce an increased amount of flexibility for Her2tG.
  • Two G3S linker subunits linked as one was also used to mimic the spacer length of the CD28hinge and IgG4 hinge. Both the CD28 hinge and IgG4 hinge have been used as spacers previously between the scFv and transmembrane region in CARs that are functional. Both the CD28hinge and IgG4hinge contain a cysteine that facilitate dimerization. While helpful for CARs, this dimerization may inhibit the flexibility of Her2t and therefore not allow for as significant recognition to Herceptin.
  • the advantage of using two G3S linkers (SEQ ID NO: 45) over three or four was to limit vector payload, eliminate potentially unnecessary sequences and at the same time achieve enhanced functionality.
  • an isolated polypeptide comprises at least 95% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER, and wherein the extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 is linked to the transmembrane domain by a sequence comprising amino acids GGGSGGGS (SEQ ID NO: 45).
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23. In some alternatives, the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23. In some alternatives, the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23. In some alternatives, the isolated polypeptide further comprises a leader peptide that provides for cell surface expression. In some alternatives, the leader peptide comprises an amino acid sequence set forth in SEQ ID NO: 17. In some alternatives, the antibody is trastuzumab.
  • T lymphocyte populations T lymphocyte populations.
  • compositions described herein provide for genetically modified host cells with the vectors and/or constructs as described herein.
  • the host cells are CD4+ and/or CD8+ T lymphocytes.
  • the host cells are precursor T cells.
  • the host cells are hematopoietic stem cells.
  • T lymphocytes can be collected in accordance with known techniques and enriched or depleted by known techniques such as affinity binding to antibodies such as flow cytometry and/or immunomagnetic selection. After enrichment and/or depletion steps, in vitro expansion of the desired T lymphocytes can be carried out in accordance with known techniques or variations thereof that will be apparent to those skilled in the art. In some alternatives, the T cells are autologous T cells obtained from the patient.
  • the desired T cell population or subpopulation can be expanded by adding an initial T lymphocyte population to a culture medium in vitro, and then adding to the culture medium feeder cells, such as non-dividing peripheral blood mononuclear cells (PBMC), (e.g., such that the resulting population of cells contains at least 5, 10, 20, or 40 or more PBMC feeder cells or an amount that is within a range defined by any two of the aforementioned amounts for each T lymphocyte in the initial population to be expanded); and incubating the culture (e.g. for a time sufficient to expand the numbers of T cells).
  • the non-dividing feeder cells can comprise gamma-irradiated PBMC feeder cells.
  • the PBMC are irradiated with gamma rays in the range of 3000 to 3600 rads to prevent cell division. In some alternatives, the PBMC are irradiated with gamma rays of 3000, 3100, 3200, 3300, 3400, 3500 or 3600 rads or any value of rads between any two endpoints of any of the listed values to prevent cell division.
  • the order of addition of the T cells and feeder cells to the culture media can be reversed if desired.
  • the culture can typically be incubated under conditions of temperature and the like that are suitable for the growth of T lymphocytes.
  • the temperature will generally be at least 25 degrees Celsius, preferably at least 30 degrees, more preferably about 37 degrees. In some alternatives, the temperature for the growth of human T lymphocytes is 22, 24, 26, 28, 30, 32, 34, 36, 37 degrees Celsius or any other temperature between any two endpoints of any of the listed values.
  • the T lymphocytes expanded include CD8 + cytotoxic T lymphocytes (CTL) and CD4 + helper T lymphocytes that can be specific for an antigen present on a human tumor or a pathogen.
  • CTL cytotoxic T lymphocytes
  • CD4 + helper T lymphocytes that can be specific for an antigen present on a human tumor or a pathogen.
  • the expansion method can further comprise the step of adding non-dividing EBV-transformed lymphoblastoid cells (LCL) as feeder cells.
  • LCL can be irradiated with gamma rays in the range of 6000 to 10,000 rads. In some alternatives, the LCL are irradiated with gamma rays in of 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500 or 10,000 rads or any amount of rads between two endpoints of any of the listed values.
  • the LCL feeder cells can be provided in any suitable amount, such as a ratio of LCL feeder cells to initial T lymphocytes of at least about 10: 1.
  • the expansion method can further comprise the step of adding anti-CD3 and/or anti CD28 antibody to the culture medium (e.g., at a concentration of at least about 0.5 ng/ml).
  • the expansion method can further comprise the step of adding IL-2 and/or IL-15 to the culture medium (e.g., wherein the concentration of IL-2 is at least aboutlO units/ml).
  • both cytotoxic and helper T lymphocytes can be sorted into naive, memory, and effector T cell subpopulations either before or after expansion.
  • CD8+ cells can be obtained by using standard methods.
  • CD8+ cells are further sorted into na ' ive, central memory, and effector memory cells by identifying cell surface antigens that are associated with each of those types of CD8+ cells.
  • memory T cells are present in both CD62L+ and CD62L- subsets of CD8+ peripheral blood lymphocytes.
  • PBMC are sorted into CD62L-CD8+ and CD62L+CD8+ fractions after staining with anti-CD8 and anti-CD62L antibodies.
  • the expression of phenotypic markers of central memory TCM include CD45RO, CD62L, CCR7, CD28, CD3, and CD127 and are negative or low for granzyme B.
  • central memory T cells are CD45RO+, CD62L+, CD8+ T cells.
  • effector TE are negative for CD62L, CCR7, CD28, and CD127, and positive for granzyme B and perforin.
  • na ' ive CD8+ T lymphocytes are characterized by the expression of phenotypic markers of na ' ive T cells including CD62L, CCR7, CD28, CD3, CD 127, and CD45RA.
  • CD4+ T helper cells are sorted into na ' ive, central memory, and effector cells by identifying cell populations that have cell surface antigens.
  • CD4+ lymphocytes can be obtained by standard methods.
  • na ' ive CD4+ T lymphocytes are CD45RO-, CD45RA+, CD62L+, CD4+ T cells.
  • central memory CD4+ cells are CD62L+ and CD45RO+.
  • effector CD4+ cells are CD62L- and CD45RO-.
  • Whether a cell or cell population is positive for a particular cell surface marker can be determined by flow cytometry using staining with a specific antibody for the surface marker and an isotype matched control antibody.
  • a cell population negative for a marker refers to the absence of significant staining of the cell population with the specific antibody above the isotype control, positive refers to uniform staining of the cell population above the isotype control.
  • a decrease in expression of one or markers refers to loss of 1 log 10 in the mean fluorescence intensity and/or decrease of percentage of cells that exhibit the marker of at least 20% of the cells, 25% of-the cells, 30% of the cells, 35% of the cells, 40% of the cells, 45% of the cells, 50% of the cells, 55% of the cells, 60% of the cells, 65% of the cells, 70% of the cells, 75% of the cells, 80% of the cells, 85% of the cells, 90%) of the cell, 95% of the cells, and 100% of the cells and any % between 20 and 100% when compared to a reference cell population or any percent range of cells between the percent values of any of the aforementioned values when compared to a reference cell population.
  • a cell population positive for one or markers refers to a percentage of cells that exhibit the marker of at least 50% of the cells, 55% of the cells, 60% of the cells, 65% of the cells, 70% of the cells, 75% of the cells, 80% of the cells, 85% of the cells, 90%) of the cell, 95% of the cells, and 100% of the cells and any percentage within a range defined by any two of the aforementioned percentages when compared to a reference cell population.
  • populations of CD4+ and CD8+ that are antigen specific can be obtained by stimulating na ' ive or antigen specific T lymphocytes with antigen.
  • antigen-specific T cell lines or clones can be generated to Cytomegalovirus antigens by isolating T cells from infected subjects and stimulating the cells in vitro with the same antigen.
  • Na ' ive T cells can also be used. Any number of antigens from tumor cells can be utilized as targets to elicit T cell responses.
  • the adoptive cellular immunotherapy compositions are useful in the treatment of a disease or disorder including a solid tumor, hematologic malignancy, breast cancer or melanoma.
  • the introduced gene or genes can improve the efficacy of therapy by promoting the viability and/or function of transferred T cells; or they can provide a genetic marker to permit selection and/or evaluation of in vivo survival or migration; or they can incorporate functions that improve the safety of immunotherapy, for example, by making the cell susceptible to controlled expression of the transgene. This can be carried out in accordance with known techniques that will be apparent to those skilled in the art based upon the present disclosure.
  • T cells are modified with vector coding for genetic tags as described herein.
  • cells are modified with a vector comprising a polynucleotide coding for a chimeric antigen receptor operably linked to a genetic tag.
  • cells are modified with a vector comprising a polynucleotide coding for a genetic tag alone.
  • the T cells are obtained from the subject to be treated, in other alternatives, the lymphocytes are obtained from allogeneic human donors, preferably healthy human donors.
  • Chimeric receptors can be constructed with a specificity for any cell surface marker by utilizing antigen binding fragments or antibody variable domains of, for example, antibody molecules.
  • the antigen binding molecules can be linked to one or more cell signaling modules.
  • cell signaling modules include CD3 transmembrane domain, CD3 intracellular signaling domains, and CD28 transmembrane domains.
  • the intracellular signaling domain comprises a CD28 transmembrane and signaling domain linked to a CD3 zeta intracellular domain.
  • the same or a different chimeric receptor can be introduced into each of population of CD4+ and CD8+ T lymphocytes.
  • the chimeric receptor in each of these populations has a ligand binding domain that specifically binds to the same ligand on the tumor or infected cell or a different antigen or epitope.
  • the cellular signaling modules can differ.
  • the intracellular signaling domain of the CD8+ cytotoxic T cells is the same as the intracellular signaling domain of the CD4+ helper T cells.
  • the intracellular signaling domain of the CD 8+ cytotoxic T cells is different than the intracellular signaling domain of the CD4+ helper T cells.
  • a method comprises introducing an isolated nucleic acid, such as a nucleic acid coding for isolated polypeptide comprising at least 95% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 511 to 652 or 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, into a host cell; and culturing the host cells in a medium comprising at least one growth factor.
  • an isolated nucleic acid such as a nucleic acid coding for isolated polypeptide comprising at least 95% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 511 to 652 or 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in
  • a method further comprises selecting the host cells for expression of Her2t before or after or both before and after the culturing step.
  • a method of manufacturing further comprises introducing a second nucleic acid coding for a second chimeric antigen receptor and a second genetic tag into the host cell.
  • the method further comprises selecting the host cells for expression of the second genetic tag before or after or both before and after the culturing step.
  • the host cells are precursor T cells.
  • the host cells are hematopoietic stem cells.
  • a method comprises introducing a first isolated nucleic acid, such as a nucleic acid coding for isolated polypeptide comprising at least 95% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 511 to 652 or 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, into a first host cell; selecting first host cells that express Her2t, introducing a second nucleic acid coding for a second chimeric antigen receptor and a second genetic tag into a second host cell, selecting second host cells for expression of the second genetic tag, and optionally, culturing the first and second host cells in a medium comprising at least one growth factor.
  • a composition comprises a first and second host cell population.
  • the host cells are precursor T cells.
  • the host cells are
  • each of the CD4 or CD8 T lymphocytes can be sorted in to naive, central memory, effector memory or effector cells prior to transduction as described herein. In some alternatives, each of the CD4 or CD8 T lymphocytes can be sorted into naive, central memory, effector memory, or effector cells after transduction.
  • naive CD4+ cells are CD45RO- , CD45RA+, CD62L+, and/or CD4+ positive T cells.
  • central memory CD4+ cells are CD62L positive and/or CD45RO positive.
  • effector CD4+ cells are CD62L negative and/or CD45RO positive.
  • memory T cells are present in both CD62L+ and/or CD62L- subsets of CD8+ peripheral blood lymphocytes.
  • PBMC are sorted into CD62L-CD8+ and/or CD62L+CD8+ fractions after staining with anti-CD8 and anti-CD62L antibodies.
  • the expression of phenotypic markers of central memory T cells include CD62L, CCR7, CD28, CD3, and/or CD127 and are negative or low for granzyme B.
  • central memory T cells are CD45RO+, CD62L+, and/or CD8+ T cells.
  • effector T cells are negative for CD62L, CCR7, CD28, and/or CD127, and positive for granzyme B and/or perforin.
  • naive CD8+ T lymphocytes are characterized by CD8+, CD62L+, CD45RO+, CCR7+, CD28+ CD127+, and/or CD45RO+. Each of these populations can be independently modified with a chimeric receptor.
  • Various transduction techniques have been developed which utilize recombinant infectious virus particles for gene delivery. This represents a currently preferred approach to the transduction of T lymphocytes of the present invention.
  • the viral vectors which have been used in this way include virus vectors derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentiviral vectors, and retroviruses.
  • virus vectors derived from simian virus 40 adenoviruses
  • AAV adeno-associated virus
  • lentiviral vectors lentiviral vectors
  • retroviruses retroviruses
  • hematopoietic or lymphoid cells including calcium phosphate transfection, protoplast fusion, electroporation, and infection with recombinant adenovirus, adeno- associated virus and retrovirus vectors.
  • Primary T lymphocytes have been successfully transduced by electroporation and by retroviral or lentiviral infection.
  • Retroviral and lentiviral vectors provide a highly efficient method for gene transfer into eukaryotic cells. Moreover, retroviral or lentiviral integration takes place in a controlled fashion and results in the stable integration of one or a few copies of the new genetic information per cell. In some alternatives, retroviral or lentiviral vectors are used for gene transfer into eukaryotic cells. In some alternatives, the cells are human cells.
  • a stimulatory factor for example, a lymphokine or a cytokine
  • a stimulatory factor for example, a lymphokine or a cytokine
  • negative selection it is meant that the infused cell can be eliminated as a result of a change in the in vivo condition of the individual.
  • the negative selectable phenotype can result from the insertion of a gene that confers sensitivity to an administered agent, for example, a compound.
  • the genetic tag Her2t also provides for negative selection in vivo.
  • an antibody that binds to Domain IV of Her2 e.g.trastuzumab
  • an antibody that competes for binding with an antibody that binds to Domain IV of Her2 is administered to the subject.
  • the antibodies contain an Fc region in order to activate antibody dependent cellular cytotoxicity reaction to kill the transduced cells.
  • the antibody or fragment thereof is linked to a cytotoxic agent. The cytotoxic conjugate binds to cells expressing CAR and her2t and kills the cells. This method provides a way to ablate administered cells that are associated with toxicity or adverse side effects.
  • HSV-I TK Herpes simplex virus type I thymidine kinase
  • HPRT cellular hypoxanthine phosphribosyltransferase
  • APRT cellular adenine phosphoribosyltransferase
  • transduction is carried out using lentiviral vectors.
  • CD4+ and CD8+ cells each can separately be modified with an expression vector encoding a chimeric receptor to form defined populations.
  • cells can be separately modified with a vector comprising a polynucleotide coding for a CAR and first genetic tag and/or and a vector comprising a polynucleotide coding for a CAR and second and different genetic tag.
  • the CAR constructs can be the same or different. For example, CD8 T cells are transduced with a CAR construct having the first genetic tag and CD4 T cells are tranduced with the same CAR with second genetic tag.
  • these cells are then further sorted into subpopulations of naive, central memory and effector cells as described above by sorting for cell surface antigens unique to each of those cell populations.
  • CD4+ or CD8+ cell populations can be selected by their cytokine profile or proliferative activities. For example, CD4+ T lymphocytes that have enhanced production of cytokines such as IL-2, IL-4, IL-10, TNFa, and/or IFNy as compared to sham transduced cells or transduced CD8+ cells when stimulated with antigen can be selected.
  • naive or central memory CD4+ T cells that have enhanced production of IL-2 and/or TNFa are selected.
  • CD8+ cells that have enhanced IFNy production are selected as compared to sham transduced CD8+ cells.
  • CD4+ or CD8+ cell populations are selected by their cytokine profile or proliferative activities.
  • CD4+ T lymphocytes that have enhanced production of cytokines such as IL-2, IL-4, IL-10, TNFa, and/or IFNy as compared to sham transduced cells or transduced CD8+ cells when stimulated with antigen are selected.
  • CD4+ and CD8+ cells are selected that are cytotoxic for antigen bearing cells.
  • CD4+ are expected to be weakly cytotoxic as compared to CD8+ cells.
  • transduced lymphocytes such as CD8+ central memory cells, are selected that provide for tumor cell killing in vivo using an animal model established for the particular type of cancer.
  • transduced cells are selected for the expression of a genetic tag.
  • cells expressing, for example, Her2t or EGFRt are selected using antibodies that bind to the genetic tags.
  • the antibodies provide for selection of cell population containing at least 80-100% cells positive for the genetic tag.
  • Selected cells can be evaluated for transgene expression using techniques such as Western blot or flow cytometry.
  • the cells selected for expression of a genetic tag are also further characterized for expression of the CAR by analyzing, for example, the amount of the stimulatory domain (e.g. CD3zeta), Protein L, and T2A.
  • cells having a ratio of about 1 :0.1 to 10:0.1 of expression of the CAR to the genetic tag are selected.
  • cells having a ratio of about 1 :0.1, 2: 0.1, 3: 0.1, 4: 0.1, 5:01, 6:0.1, 7:0.1, 8:0.1, 9:01, or 10:0.1 of expression of the CAR to the genetic tag, or any other ratio of the CAR to the genetic tag that is between any of the listed ratios are selected.
  • the Her2t genetic tag can be utilized in cases where the expression of the CAR is low as it provides better transgene expression levels than EGFRt.
  • a Her2t genetic tag provides for at least a 1.5 fold, 2 fold, 5 fold, or 10 fold increase in transgene expression as compared to EGFRt genetic tag, or any other fold increase between any two of the listed values.
  • transduced chimeric receptor expressing T cells are selected that can persist in vivo using an animal model established for the particular type of cancer.
  • transduced chimeric receptor CD8+ central memory cells have been shown to persist in vivo after introduction into the animal for about 3 day or more, 10 days or more, 20 days or more, 30 days or more, 40 days or more, or 50 days or more, or any other time between any two of the listed values. Persistence in vivo can be determined by imaging with a detectably labeled antibody that binds to a genetic tag, such as Her2t or EGFRt.
  • combinations of CD4+ and CD8+ T cells will be utilized in the compositions.
  • combinations of chimeric receptor transduced CD4+ cells can be combined with chimeric receptor transduced CD8+ cells of the same ligand specificity or combined with CD8 + T cells that are specific for a distinct tumor ligand and different genetic tag.
  • chimeric receptor transduced CD8+ cells are combined with chimeric receptor transduced CD4+ cells specific for a different ligand expressed on the tumor.
  • chimeric receptor modified CD4+ and CD8+ cells are combined.
  • CD8+ and CD4+ cells can be combined in different ratios for example, a 1 : 1 ratio of CD8+ and CD4+, a ratio of 10: 1 of CD8+ to CD4+, or a ratio of 100: 1 of CD8+ to CD4+, or any other ratio of CD8+ to CD4+ that is between any two of the listed ratio values.
  • the combined population is tested for cell proliferation in vitro and/or in vivo, and the ratio of cells that provides for proliferation of cells is selected.
  • the cell populations are preferably expanded in vitro until a sufficient number of cells are obtained to provide for at least one infusion into a human subject, typically around 10 4 cells/kg to 10 9 cells/kg.
  • the transduced cells are cultured in the presence of antigen bearing cells, anti CD3, anti CD28, and IL 2, IL-7, IL 15, and/or IL-21 and combinations thereof.
  • Each of the subpopulations of CD4+ and CD8+ cells can be combined with one another.
  • modified na ' ive or central memory CD4+ cells are combined with modified central memory CD8+ T cells to provide a synergistic cytotoxic effect on antigen bearing cells, such as tumor cells.
  • the disclosure provides for an adoptive cellular immunotherapy composition comprising a genetically modified T lymphocyte cell preparation as described herein.
  • the T lymphocyte cell preparation comprises CD4 + T cells that have a chimeric receptor comprising an extracellular antibody variable domain specific for a ligand associated with the disease or disorder, a spacer region, a transmembrane domain, and an intracellular signaling domain of a T cell receptor and a genetic tag as described herein.
  • an adoptive cellular immunotherapy composition further comprises a chimeric receptor modified tumor-specific CD8+ cytotoxic T lymphocyte cell preparation that provides a cellular immune response, wherein the cytotoxic T lymphocyte cell preparation comprises CD 8+ T cells that have a chimeric receptor comprising an extracellular single chain antibody specific for a ligand associated with the disease or disorder, a spacer region, a transmembrane domain, and an intracellular signaling domain of a T cell receptor and a genetic tag as described herein.
  • the chimeric receptor modified T cell population of the disclosure can persist in vivo for at least about 3 days or longer. In alternative each of these populations can be combined with one another or other cell types to provide a composition.
  • a host cell comprises an isolated nucleic acid, such as a nucleic acid coding for an isolated polypeptide comprising at least 95% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 511 to 652 or 563 to 652 of SEQ ID NO:23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and a second nucleic acid coding for a second chimeric antigen receptor and a second genetic tag.
  • the host cells are precursor T cells.
  • the host cells are hematopoietic stem cells.
  • a composition comprises a first host cell comprising a first isolated nucleic acid, such as a nucleic acid coding for an isolated polypeptide comprising at least 95% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 511 to 652 or 563 to 652 of SEQ ID NO:23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and a second host cell comprising a second nucleic acid coding for a second chimeric antigen receptor and a second genetic tag.
  • a first isolated nucleic acid such as a nucleic acid coding for an isolated polypeptide comprising at least 95% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 511 to 652 or 563 to 652 of SEQ ID NO:23 linked to a transmembrane domain, wherein the isolated poly
  • first host cell and the second host cell can be the same or different type of host cells, for example, the first host cell can be a CD8 central memory cells and the second host cell can be a naive CD4 cell.
  • first and second host cells are each selected from the group consisting of CD8 T cells, CD4 T cells,CD4 na ' ive T cells, CD8 na ' ive T cells, CD8 central memory cells, CD4 central memory cells, and combinations thereof.
  • the CD4+ T helper lymphocyte cell is selected from the group consisting of na ' ive CD4+ T cells, central memory CD4+ T cells, effector memory CD4+ T cells, or bulk CD4+ T cells.
  • CD4+ helper lymphocyte cell is a na ' ive CD4+ T cell, wherein the na ' ive CD4+ T cell comprises a CD45RO-, CD45RA+, CD62L+ CD4+ T cell.
  • the CD8+ T cytotoxic lymphocyte cell is selected from the group consisting of na ' ive CD8+ T cells, central memory CD8+ T cells, effector memory CD8+ T cells or bulk CD8+ T cells.
  • the CD8+ cytotoxic T lymphocyte cell is a central memory T cell wherein the central memory T cell comprises a CD45RO+, CD62L+, CD8+ T cell.
  • the CD8+ cytotoxic T lymphocyte cell is a central memory T cell and the CD4+ helper T lymphocyte cell is a naive or central memory CD4+ T cell.
  • the disclosure provides methods of making adoptive immunotherapy compositions and uses or methods of using these compositions for performing cellular immunotherapy in a subject having a disease or disorder.
  • a method comprises introducing an isolated nucleic acid, such as a nucleic acid coding for isolated polypeptide comprising at least 95% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 511 to 652 or 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, into a host cell; and culturing the host cells in a medium comprising at least one growth factor.
  • an isolated nucleic acid such as a nucleic acid coding for isolated polypeptide comprising at least 95% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 511 to 652 or 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in
  • a method further comprises selecting the host cells for expression of Her2t before or after or both before and after the culturing step.
  • a method of manufacturing further comprises introducing a second nucleic acid coding for a second chimeric antigen receptor and a second genetic tag into the host cell.
  • the method further comprises selecting the host cells for expression of the second genetic tag before or after or both before and after the culturing step.
  • the host cells are precursor T cells.
  • the host cells are hematopoietic stem cells.
  • a method further comprises obtaining a modified CD8+ central memory T cell, wherein the modified central memory CD8 T lymphocyte cell preparation comprises CD8+ cells that have a chimeric receptor comprising a ligand binding domain specific for a tumor cell surface molecule, a spacer domain, a transmembrane domain, and an intracellular signaling domain and a genetic tag as described herein.
  • CD8+ cells have a cytokine or chemokine receptor under the control of an inducible promoter.
  • modified CD4+ T cells and modified CD8+ cytotoxic T cell can be the same or different.
  • modified CD4+ T cells that have a first CAR and first genetic tag while the CD 8+ cytotoxic T cell comprises CD8+ cells that have a second and different CAR and second and different genetic tag.
  • the polynucleotide can code for a chimeric antigen receptor that is the same in both the CD4+ and the CD8+ cell population.
  • the difference between the two CAR constructs can include the specificity or affinity of the ligand binding domain for an antigen or epitope, the length and sequence of the spacer region, and the intracellular signaling components.
  • CD4+ and CD8+ cells that are modified with a chimeric receptor has been described above as well as in the examples.
  • Antigen specific T lymphocytes can be obtained from a patient having the disease or disorder or can be prepared by in vitro stimulation of T lymphocytes in the presence of antigen. Subpopulations of CD4+ and CD8+ T lymphocytes that are not selected for antigen specificity can also be isolated as described herein and combined in the methods of manufacturing. Cell populations are advantageously selected for expression of one or more genetic tags, such as Her2t and/or EGFRt.
  • the combination of cell populations can be evaluated for uniformity of cell surface makers, the ability to proliferate through at least two generations, to have a uniform cell differentiation status.
  • Quality control can be performed by determining the ratio of expression of CAR to the expression of the genetic tag.
  • Cell differentiation status and cell surface markers on the chimeric receptor modified T cells can be determined by flow cytometry.
  • the markers and cell differentiation status on the CD8+ cells include CD3, CD8, CD62L, CD28, CD27, CD69, CD25, PD-1, CTLA-4, CD45RO, and/or CD45RA.
  • the markers and the cell differentiation status on the CD4+ cells include CD3, CD4, CD62L, CD28, CD27, CD69, CD25, PD-1, CTLA-4 CD45RO, and/or CD45RA.
  • Proliferation and persistence of the chimeric receptor modified T cells can be determined by using an animal model of the disease or disorder and administering the cells and determining persistence and/ or proliferative capacity of the transferred cells by detecting the cells using a detectably labeled antibody that binds to the genetic tag such as Erbitux(EGFRt) and/or Herceptin (Her2t).
  • a detectably labeled antibody that binds to the genetic tag such as Erbitux(EGFRt) and/or Herceptin (Her2t).
  • a detectably labeled antibody that binds to the genetic tag such as Erbitux(EGFRt) and/or Herceptin (Her2t).
  • a detectably labeled antibody that binds to the genetic tag such as Erbitux(EGFRt) and/or Herceptin (Her2t).
  • antibody or antigen binding fragments to detect transgene expressing cells in vivo
  • antibody or antigen binding fragment preferably does not include a Fc portion in order to minimize any ADCC
  • Alternatives include a method of treating patient having cancer expressing a tumor antigen comprises administering an effective amount of a compositions as described herein, wherein the cells of the composition express a chimeric antigen receptor that comprises an antigen binding domain that binds to the tumor antigen expressed on the cancer cell and a genetic tag.
  • the cancer has a tumor antigen recognized by the chimeric antigen receptor on the cells.
  • the cancer is selected from the group consisting of breast cancer, diffuse large B cell lymphoma, lymphoma, ALL, CLL, and multiple myeloma.
  • a method of treating patient having cancer expressing a tumor antigen comprises administering an effective amount of a compositions as described herein, wherein the cells of the composition express a first chimeric antigen receptor that comprises an antigen binding domain that binds to the tumor antigen expressed on the cancer cell and a first genetic tag and a second chimeric antigen receptor that comprises an antigen binding domain that binds to the tumor antigen expressed on the cancer cell and a second genetic tag.
  • a method of treating patient having cancer expressing a tumor antigen comprises administering an effective amount of a composition comprising a first host cell that expresses a first chimeric antigen receptor that comprises an antigen binding domain that binds to the tumor antigen expressed on the cancer cell and a first genetic tag and a second host cell comprising a second chimeric antigen receptor that comprises an antigen binding domain that binds to the tumor antigen expressed on the cancer cell and a second genetic tag.
  • the host cells are precursor T cells.
  • the host cells are hematopoietic stem cells.
  • a method of treating a patient having cancer and/or expressing a tumor antigen comprises administering an effective amount of a composition as described herein and an antibody that specifically binds to the genetic tag, wherein the cells of the composition express a chimeric antigen receptor that comprises an antigen binding domain that binds to the tumor antigen expressed on the cancer cell and a genetic tag.
  • the antibody binds to Domain IV of Her2, or binds to EGFRt.
  • the antibodies are Herceptin or Erbitux.
  • an antibody is detectably labelled in order to allow tracking of the cells in vivo.
  • the antibody or antigen binding fragment when the antibody is used for detection in vivo, it is preferred that the antibody or antigen binding fragment lacks all or a portion of the Fc region in order to avoid ADCC reactions.
  • Detectable labels include biotin, His tags, myc tags, radiolabels, and/or fluorescent labels. In some alternatives the detectable labels comprise biotin, His tags, myc tags, radiolabels, and/or fluorescent labels.
  • a method comprises administering to the subject a genetically modified cytotoxic T lymphocyte cell preparation that provides a cellular immune response, wherein the cytotoxic T lymphocyte cell preparation comprises CD8 + T cells that have a chimeric receptor comprising a ligand binding domain specific for a tumor cell surface molecule, a spacer domain, a transmembrane domain, and an intracellular signaling domain and a first genetic tag as described herein, and/or a genetically modified helper T lymphocyte cell preparation that elicits direct tumor recognition and augments the genetically modified cytotoxic T lymphocyte cell preparations ability to mediate a cellular immune response, wherein the helper T lymphocyte cell preparation comprises CD4+ T cells that have a chimeric receptor comprising a ligand binding domain specific for a tumor cell surface molecule, a spacer domain, a transmembrane domain, and an intracellular signaling domain and a second genetic tag.
  • the methods are useful in the treatment of, for example, hematologic malignancy, melanoma, breast cancer, and other epithelial malignancies or solid tumors.
  • the molecule associated with the disease or disorder is selected from the group consisting of orphan tyrosine kinase receptor ROR1, Her2, EGFR, CE7, hB7H3, CD 19, CD20, CD22, mesothelin, CEA, and hepatitis B surface antigen.
  • the cells are formulated by first harvesting them from their culture medium, and then washing and concentrating the cells in a medium and container system suitable for administration (a "pharmaceutically acceptable" carrier) in a treatment-effective amount.
  • a medium and container system suitable for administration a "pharmaceutically acceptable” carrier
  • Suitable infusion medium can be any isotonic medium formulation, typically normal saline, Normosol R (Abbott) or Plasma-Lyte A (Baxter), but also 5% dextrose in water or Ringer's lactate can be utilized.
  • the infusion medium can be supplemented with human serum albumin, fetal bovine serum or other human serum components.
  • a treatment effective amount of cells in the composition is a transduced CD4 or CD8 cell or at least 2 cell subsets (for example, 1 CD8+ central memory T cell subset and 1 CD4+ helper T cell subset) or is more typically greater than 10 2 cells, and up to 10 6 , up to and including 10 8 or 10 9 cells and can be more than 10 10 cells or any amount of cells defined between any two endpoints of any of the listed values.
  • the number of cells will depend upon the ultimate use for which the composition is intended, as will the type of cells included therein. For example, if cells that are specific for a particular antigen are desired, then the population will contain greater than 70%, generally greater than 80%>, 85% and 90-95%) of such cells or any percent amount of cells within a range defined by any two of the aforementioned percentages.
  • the cells are generally in a volume of a liter or less but greater than lnl, can be 500 mis or less but greater than lnl, even 250 mis or 100 mis or less but greater than lnl, or any volume defined between two endpoints of any of the listed values.
  • the density of the desired cells is typically greater than 10 4 cells/ml and generally is greater than 10 7 cells/ml, generally 10 8 cells/ml or greater.
  • the clinically relevant number of immune cells can be apportioned into multiple infusions that cumulatively equal or exceed 10 6 , 10 7 , 10 8 , 10 8 , 10 9 , 10 10 or 10 11 cells or any amount of cells within a range defined by two of the aforementioned amounts.
  • the lymphocytes can be used to confer immunity to individuals.
  • immuno is meant a lessening of one or more physical symptoms associated with a response to infection by a pathogen, or to a tumor, to which the lymphocyte response is directed.
  • the amount of cells administered is usually in the range present in normal individuals with immunity to the pathogen.
  • the cells are usually administered by infusion, with each infusion in a range of from 2 cells, up to at least 10 6 to 3xl0 10 cells, preferably in the range of at least 10 7 to 10 9 cells or any amount of cells within a range defined by two of the aforementioned amounts.
  • the T cells can be administered by a single infusion, or by multiple infusions over a range of time.
  • T lymphocytes including cytotoxic T lymphocytes and/or helper T lymphocytes
  • compositions as described herein are administered intravenously, intraperitoneally, intratumorly, into the bone marrow, into the lymph node, and/or into cerebrospinal fluid.
  • the chimeric receptor engineered compositions are delivered to the site of the tumor.
  • the compositions as described herein can be combined with a compound that targets the cells to the tumor or the immune system compartments and avoid sites such as the lung.
  • compositions as described herein are administered with chemotherapeutic agents and/or immunosuppressants.
  • a patient is first treated with a chemotherapeutic agent that inhibits or destroys other immune cells followed by the compositions described herein.
  • chemotherapy can be avoided entirely.
  • the present invention is illustrated further in the examples set forth below.
  • an isolated polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2.
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23. In some alternatives, the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23. In some alternatives, the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23. In some alternatives, the isolated polypeptide further comprises a leader peptide that provides for cell surface expression. In some alternatives, the leader peptide has the sequence of SEQ ID NO: 17. In some alternatives, the antibody is trastuzumab.
  • an isolated polypeptide comprising at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER, and wherein the extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 is linked to the transmembrane domain by a sequence comprising amino acids GGGSGGGS (SEQ ID NO: 45).
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23. In some alternatives, the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23. In some alternatives, the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23. In some alternatives, the isolated polypeptide further comprises a leader peptide that provides for cell surface expression. In some alternatives, the leader peptide comprises an amino acid sequence set forth in SEQ ID NO: 17. In some alternatives, the antibody is trastuzumab.
  • an isolated nucleic acid wherein the isolated nucleic acid encodes a polypeptide.
  • the isolated polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2.
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23. In some alternatives, the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23. In some alternatives, the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23. In some alternatives, the isolated polypeptide further comprises a leader peptide that provides for cell surface expression. In some alternatives, the leader peptide has the sequence of SEQ ID NO: 17. In some alternatives, the antibody is trastuzumab.
  • the isolated polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER, and wherein the extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 is linked to the transmembrane domain by a sequence comprising amino acids GGGSGGGS (SEQ ID NO: 45).
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23. In some alternatives, the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23. In some alternatives, the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23. In some alternatives, the isolated polypeptide further comprises a leader peptide that provides for cell surface expression. In some alternatives, the leader peptide comprises an amino acid sequence set forth in SEQ ID NO: 17. In some alternatives, the antibody is trastuzumab. In some alternatives, the isolated nucleic acid further comprises a promoter.
  • the isolated nucleic acid further comprises a transgene.
  • the transgene comprises a polynucleotide encoding a chimeric antigen receptor.
  • the chimeric antigen receptor comprises an antigen binding domain, a spacer domain, a transmembrane domain and at least one stimulatory domain.
  • the polynucleotide encoding the transgene is linked to the nucleic acid encoding the HER2 polypeptide with a self-cleaving linker.
  • the HER2 polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2.
  • the self-cleaving linker is a T2A linker having the sequence of L E G G G E G R G S L L T C G (SEQ ID NO: 26).
  • the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 2. In some alternatives, the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 25 (CD20CAR). In some alternatives, the size of the isolated nucleic acid comprises a size of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14.9 Kb, or any size in between any two of the construct size listed.
  • a host cell comprising an isolated nucleic acid, wherein the isolated nucleic acid encodes a polypeptide.
  • the isolated polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2.
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23. In some alternatives, the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23. In some alternatives, the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23. In some alternatives, the isolated polypeptide further comprises a leader peptide that provides for cell surface expression. In some alternatives, the leader peptide has the sequence of SEQ ID NO: 17. In some alternatives, the antibody is trastuzumab.
  • the isolated polypeptide comprises at least 95%, 96%, 97%), 98%o, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER, and wherein the extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 is linked to the transmembrane domain by a sequence comprising amino acids GGGSGGGS (SEQ ID NO: 45).
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23. In some alternatives, the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23. In some alternatives, the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23. In some alternatives, the isolated polypeptide further comprises a leader peptide that provides for cell surface expression. In some alternatives, the leader peptide comprises an amino acid sequence set forth in SEQ ID NO: 17. In some alternatives, the antibody is trastuzumab. In some alternatives, the isolated nucleic acid further comprises a promoter.
  • the isolated nucleic acid further comprises a transgene.
  • the transgene comprises a polynucleotide encoding a chimeric antigen receptor.
  • the chimeric antigen receptor comprises an antigen binding domain, a spacer domain, a transmembrane domain and at least one stimulatory domain.
  • the polynucleotide encoding the transgene is linked to the nucleic acid encoding the HER2 polypeptide with a self-cleaving linker.
  • the HER2 polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2.
  • the self-cleaving linker is a T2A linker having the sequence of L E G G G E G R G S L L T C G (SEQ ID NO: 26).
  • the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 2. In some alternatives, the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 25 (CD20CAR).
  • the host cell is selected from the group consisting of CD8 T cells, CD4 T cells, CD4 naive T cells, CD8 naive T cells, CD8 central memory cells, and CD4 central memory cells, or combinations thereof. In some alternatives, the host cell is autologous. In some alternatives, the host cell is antigen specific. In some alternatives, the host cells are precursor T cells. In some alternatives, the host cells are hematopoietic stem cells. In some alternatives, the size of the isolated nucleic acid comprises a size of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14.9 Kb, or any size in between any two of the construct size listed.
  • a composition comprising host cells wherein the host cells comprise an isolated nucleic acid, wherein the isolated nucleic acid encodes a polypeptide.
  • the isolated polypeptide comprises at least 95%, 96%), 97%), 98%), or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2.
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23. In some alternatives, the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23. In some alternatives, the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23. In some alternatives, the isolated polypeptide further comprises a leader peptide that provides for cell surface expression. In some alternatives, the leader peptide has the sequence of SEQ ID NO: 17. In some alternatives, the antibody is trastuzumab.
  • the isolated polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER, and wherein the extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 is linked to the transmembrane domain by a sequence comprising amino acids GGGSGGGS (SEQ ID NO: 45).
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23. In some alternatives, the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23. In some alternatives, the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23. In some alternatives, the isolated polypeptide further comprises a leader peptide that provides for cell surface expression. In some alternatives, the leader peptide comprises an amino acid sequence set forth in SEQ ID NO: 17. In some alternatives, the antibody is trastuzumab. In some alternatives, the isolated nucleic acid further comprises a promoter.
  • the isolated nucleic acid further comprises a transgene.
  • the transgene comprises a polynucleotide encoding a chimeric antigen receptor.
  • the chimeric antigen receptor comprises an antigen binding domain, a spacer domain, a transmembrane domain and at least one stimulatory domain.
  • the polynucleotide encoding the transgene is linked to the nucleic acid encoding the HER2 polypeptide with a self-cleaving linker.
  • the HER2 polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2.
  • the self-cleaving linker is a T2A linker having the sequence of L E G G G E G R G S L L T C G (SEQ ID NO: 26).
  • the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 2. In some alternatives, the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 25 (CD20CAR).
  • the host cell is selected from the group consisting of CD8 T cells, CD4 T cells, CD4 naive T cells, CD8 na ' ive T cells, CD8 central memory cells, and CD4 central memory cells, or combinations thereof. In some alternatives, the host cell is autologous. In some alternatives, the host cell is antigen specific. In some alternatives, the host cells are precursor T cells. In some alternatives, the host cells are hematopoietic stem cells. In some alternatives, the size of the isolated nucleic acid comprises a size of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14.9 Kb, or any size in between any two of the construct size listed.
  • a method of manufacturing a composition comprising introducing an isolated nucleic acid into a host cell and culturing the host cells in a medium comprising at least one growth factor.
  • the isolated nucleic acid encodes a polypeptide.
  • the isolated polypeptide comprises at least 95%, 96%>, 97%, 98%>, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2.
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23.
  • the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23.
  • the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23.
  • the isolated polypeptide further comprises a leader peptide that provides for cell surface expression.
  • the leader peptide has the sequence of SEQ ID NO: 17.
  • the antibody is trastuzumab.
  • the isolated polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER, and wherein the extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 is linked to the transmembrane domain by a sequence comprising amino acids GGGSGGGS (SEQ ID NO: 45).
  • the HER2 polypeptide comprises amino acids glutamic acid 580, aspartic acid 582, aspartic acid 592, phenylalanine 595, and glutamine 624 of SEQ ID NO: 23. In some alternatives, the HER2 polypeptide comprises amino acids 563-652 of SEQ ID NO: 23. In some alternatives, the transmembrane domain comprises amino acids 653-675 of SEQ ID NO: 23. In some alternatives, the isolated polypeptide further comprises a leader peptide that provides for cell surface expression. In some alternatives, the leader peptide comprises an amino acid sequence set forth in SEQ ID NO: 17. In some alternatives, the antibody is trastuzumab. In some alternatives, the isolated nucleic acid further comprises a promoter.
  • the isolated nucleic acid further comprises a transgene.
  • the transgene comprises a polynucleotide encoding a chimeric antigen receptor.
  • the chimeric antigen receptor comprises an antigen binding domain, a spacer domain, a transmembrane domain and at least one stimulatory domain.
  • the polynucleotide encoding the transgene is linked to the nucleic acid encoding the HER2 polypeptide with a self-cleaving linker.
  • the HER2 polypeptide comprises at least 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide of an extracellular domain of HER2 polypeptide having a sequence of amino acids 563 to 652 of SEQ ID NO: 23 linked to a transmembrane domain, wherein the isolated polypeptide specifically binds to an antibody that binds to an epitope in Domain IV of Her2, and wherein the isolated polypeptide excludes the full length mature HER2.
  • the self-cleaving linker is a T2A linker having the sequence of L E G G G E G R G S L L T C G (SEQ ID NO: 26).
  • the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 2. In some alternatives, the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 25 (CD20CAR).
  • the host cell is selected from the group consisting of CD8 T cells, CD4 T cells, CD4 na ' ive T cells, CD8 na ' ive T cells, CD8 central memory cells, and CD4 central memory cells, or combinations thereof. In some alternatives, the host cell is autologous. In some alternatives, the host cell is antigen specific. In some alternatives, the growth factor is selected from IL-15, IL-7, IL-21, or IL-2, and combinations thereof.
  • the method further comprises selecting cells that express the Her2t polypeptide. In some alternatives, the cells are selected before culturing the cells in the medium. In some alternatives, the cells are selected using an antibody that binds to Domain IV of Her2. In some alternatives, the antibody is trastuzumab. In some alternatives, the method further comprises introducing a second isolated nucleic acid coding for a chimeric antigen receptor linked to a second genetic tag. In some alternatives, the method further comprises selecting cells expressing the second genetic tag. In some alternatives, the second genetic tag comprises EGFRt.
  • Fluorochrome-conjugated isotype controls, anti-CD3, CD4, CD8, CD45, Her2, and streptavidin were obtained from BD Biosciences.
  • Cetuximab (Erbitux) and trastuzumab (Herceptin) were purchased from the Seattle Children's Hospital. Erbitux and Herceptin were biotinylated (Pierce) or directly conjugated to APC (Solulink), according to manufacturer's instructions.
  • Data acquisition was performed on an LSRFortessa (BD Biosciences), and the percentage of cells in a region of analysis was calculated using Flow Jo data analysis software.
  • Epstein-Barr virus-transformed lymphoblastoid cell lines were made from peripheral blood mononuclear cells (PBMCs) as previously described (Pelloquin et al. 1986).
  • GFP:ffluc-expressing cell lines were transduced with GFP:ffluc_epHIV7 and sorted using the BD FACSJazz sorter.
  • the CD20CAR-T2A-EGFRt_epHIV7 contains a Leu 16 (murine anti- human CD20) scFv fused to the human IgG4Hinge-CH3 (119 aa) spacer domain portion of IgG4 along with the same signaling components of the CD19CAR (4-lBB-zeta). (Table 9)
  • Her2t was synthesized by PCR, using pDONR223-ErbB2 (Addgene) as a template and the epHIV7 lentiviral vector as a recipient.
  • the final product, Her2t_epHIV7 contains the human granulocyte-macrophage colony stimulating factor receptor leader peptide (GMCSFRss) fused in frame to domain IV (aa 563-652) and the transmembrane spanning components of Her2 (aa 653-675).
  • Her2t replaced EGFRt in the CD19CAR-T2A-EGFRt_epHIV7 construct by PCR and Gibson cloning.
  • EGFRt was synthesized as previously described (Wang et al. 2011). (Table 7)
  • CD 19CAR-T2A-Her2t-, CD 19CAR-T2A-EGFRt-, CD20CAR-T2A- EGFRt-, Her2t-, and EGFRt-encoding lentiviruses were produced in 293T cells using the packaging vectors pCHGP-2, pCMV-Rev2, and pCMV-G.
  • PBMCs from each donor were split into two groups (CD4 or
  • CD8 isolation kits and anti-CD45RA microbeads (Miltenyi Biotec), per the manufacturer's protocol. The depleted fraction was then positively selected on AutoMACS using anti-CD45RA microbeads (Miltenyi Biotec), per the manufacturer's protocol. The depleted fraction was then positively selected on AutoMACS using anti-CD45RA microbeads (Miltenyi Biotec), per the manufacturer's protocol. The depleted fraction was then positively selected on AutoMACS using anti-
  • CD62L microbeads to produce CD4 + CD45RO + CD62L + or CD8 + CD45RO + CD62L + central memory T cells. Isolated cells were then stimulated with 50U/ml interleukin-2 (IL-2),
  • IL-15 interleukin-15
  • anti-CD3/CD28 beads Life Technologies.
  • Primary T cell lines were transduced on day 3 after activation using protamine sulfate (1 : 100 dilution) and a virus MOI of 1 followed by centrifugation at 800 x g for 45 minutes at 32°C. All other cell lines were similarly transduced at a low cell passage number.
  • the Her2t + or EGFRt + subset of each cell line was enriched by immunomagnetic selection with biotin-conjugated Herceptin or Erbitux and anti-biotin microbeads (Miltenyi).
  • Selected CD19 or CD20CAR + T cells were expanded 12-18 days post transduction by stimulation with irradiated (8000 rad) TM-LCLs at a T cell:TM-LCL ratio of 1 :7 in the presence of 50U/ml IL-2 and 2ng/ml of IL-15.
  • CD19CAR-T2A-Her2t + /CD20CAR-T2A-EGFRt + T cells were sorted using biotinylated Herceptin and anti-biotin multisort microbeads (Miltenyi) followed by bead removal, Erbitux-APC cell labeling, and anti-APC microbeads (Miltenyi).
  • Cell lysis was carried out in RIPA buffer containing protease inhibitor cocktail.
  • Cell lysates were analyzed by BCA assay (Pierce), equally loaded onto gels and western blots were probed with the primary antibodies Her2 and phospho-Her2 (Cell Signaling Technology), anti CD247 ⁇ 3 ⁇ ), biotinylated Herceptin, or anti-P-actin (loading control).
  • Secondary IRDye 800CW conjugated Streptavidin or goat anti-mouse or rabbit (LI- COR) was added as per the manufacturer's instructions. Blots were imaged on the Odyssey Infrared Imaging System (LI-COR).
  • Cytotoxicity Four-hour chromium release assays were performed as previously described (Wang et al. 2011). Antibody-dependent cell-mediated cytotoxicity (ADCC) was determined using up to 2.5 x 10 5 Tcm cells expressing CD19CAR with Her2t marker, CD20CAR with EGFRt marker, CD 19CAR-Her2t and CD20CAREGFRt, and CD19CAR with EGFRt as a marker sequence as effector cells in co-cultures with 5 x 10 3 Cr 51 -labeled K562 cell expressing either CD 19 or CD20.
  • ADCC Antibody-dependent cell-mediated cytotoxicity
  • Cytokine secretion T cells (5 x 10 5 ) were plated in triplicate with target cells at an E:T ratio of 2: 1 in a 96-well plate and supernatants were analyzed by cytometric bead array using a Bio-Plex Human Cytokine Panel (Bio-Rad), according to the manufacturer's instructions.
  • Proliferation T cells were labeled with 0.2 ⁇ carboxyfluorescein succinimidyl ester (CFSE; Invitrogen), washed, and plated in triplicate with stimulator cells in medium without exogenous cytokines. After 72 hours of incubation, cells were labeled with anti-CD3 and live/dead stain, and subsequently analyzed by flow cytometry to assess cell division of viable CD3 + cells.
  • CFSE carboxyfluorescein succinimidyl ester
  • Engraftment Six- to 10-week old NOD/Scid IL2RyCnull mice were injected intravenously on day 0 with 10 7 of either Her2t/EGFRt-negative (Mock) or Her2t or EGFRt-selected T cells and subcutaneously with 5 x 10 6 viable NS0-IL15 cells to provide a systemic supply of human IL-15 in vivo. Bone marrow was harvested from killed animals 14 days later, and cell suspensions were analyzed by flow cytometry using anti-CD45, live/dead, CD4, CD8, biotinylated Herceptin or Erbitux, and streptavidin-APC provided by BD Biosciences.
  • femurs were fixed in 10% formalin for 24 hours, decalcified for 2 hours (Richard-Allan Scientific), and embedded in paraffin for immunohistochemical staining with anti-CD45 (DAKO), anti-EGFR (clone 31G7; Invitrogen) according to the manufacturer's instructions, or biotinylated Herceptin and SA-AF647 followed by counterstain with Hoechst.
  • DAKO anti-CD45
  • anti-EGFR clone 31G7; Invitrogen
  • biotinylated Herceptin and SA-AF647 followed by counterstain with Hoechst.
  • Her2 + or Her2t + cell lines were adhered to slides using poly-L-Lysine and then stained using biotinylated Herceptin and SA-AF647. Fluorescent images were acquired using the Nuance FX Biomarker Imaging System.
  • Her2t is devoid of all Her2 intracellular components, yet contains the Her2 transmembrane region, a conformationally intact binding epitope recognized by the monoclonal antibody trastuzumab (Herceptin) and a GMCSFRss to facilitate surface expression (Figure 1 panel B).
  • Her2t construct Three variants of the Her2t construct, one containing the full Her2 Domain IV and two minimal conformational epitopes designed based on the three dimensional structure of Her2 in complex with Herceptin (Garrett et al 2007; Cho et al 2003), were initially incorporated into the lentiviral packaging plasmid epHIV7 and characterized in CHO cells.
  • the Her2t construct including amino acids 563-652 outlined in Figure 1 panel B displayed the greatest transient surface expression based on flow analysis using biotinylated Herceptin and a streptavidin-conjugated fluorophore and was therefore chosen for further downstream characterization (data not shown).
  • Her2t is a viable and functionally inert genetic tag.
  • the Her2t-containing epHIV7 was subjected to VSV-g pseudotyped self-inactivating lentivirus production. The resultant virus was then transduced into multiple cell types resulting in 8.2-65% Her2t + populations (data not shown), with transduced K562 erythroleukemia cells (13.8% Her2t + ) as a representative ( Figure 2 panel A).
  • the transduced K562 population was subjected to a two-step immunomagnetic purification process using biotinylated Herceptin and anti-biotin microbeads.
  • Her2t is devoid of extracellular Domains I-III and contains a Domain IV binding epitope necessary for antibody recognition. It was therefore predicted that Her2t would be incapable of binding to commercial Her2 antibodies and would be uniquely recognized by Herceptin. Flow analyses confirmed that Herceptin could efficiently recognize and stain Her2t and full Her2- expressing K562 cells, while a commercial antibody was only able to recognize full Her2 (Figure 2 panel C).
  • Her2t is a highly stringent and complementary selection epitope for T cell therapy.
  • CAR chimeric antigen receptor
  • T cell therapeutics coined EGFRt were previously identified (Wang et al 2011). It was examined whether the coordinate expression of Her2t in CAR-containing viral vectors might facilitate the clinical use of ex vivo engineered, broad-scope CAR therapeutics. Furthermore, Her2t diversifies the repertoire of available, non-immunogenic selection markers for CAR-redirected T cell therapeutics and can act as an alternative or supplement to EGFRt selection strategies (i.e. rendering a T cell bispecific against multiple candidate tumor antigens).
  • the CD4 + or CD8 + Tcm transduced with a single CAR- containing vector were 22-72% Her2t or EGFRt pre-immunomagnetic selection using biotinylated Herceptin (Her2t) or Erbitux (EGFRt) and anti-biotin microbeads, but were consistently enriched to uniform purity (>90%) post-selection (Figure 3 B).
  • Dual Her2t + and EGFRt + transduced cells were alternatively immunomagnetically sorted using a combination of multisort and anti-APC beads (Materials and Methods) resulting in >90% dual transgene- positive cells (Figure 6).
  • dual-transduced cell lines can be sorted using free biotin or streptavidin as an alternative to bead removal.
  • MFI flow mean fluorescence intensity
  • Dual-selected Tcm maintain effector phenotype and target specificity in vitro.
  • CD 19- and CD20-CAR mediated by surface marker (Her2t and EGFRt) selection could enhance the functional attributes of CAR redirected T cells, the in vitro function of dual
  • CD 19- and CD20-CAR expressing conferred similar levels of specific lysis against K562 cells that express CD 19, CD20, or both ( Figure 4 panel A) but did not mediate recognition of the CD197CD20 " parental K562 targets ( Figure 4 panel B).
  • the paired functionality of the dual CAR-expressing Tcm against a K562 target panel was next tested ( Figure 4 panel B) and demonstrate that only the dual CAR- expressing Tcm were able to confer specific lysis against all target expressing K562 cells.
  • the CD 19- or CD20-specific CAR expressing Tcm cells were only able to trigger cytolytic activity against K562 cells expressing their cognate target antigens (Figure 4 panel B)
  • Her2t-selected CD19CAR-expressing Tcm produced a more diverse and enhanced cytokine profile (e.g. about 2-3 fold greater) relative to their EGFRt-selected counterpart.
  • Figure 3 panel D This can be due to the stringent nature of Her2t selection and the resultant enhancement of total CAR expression in Her2t-selected Tcm.
  • Her2t + cells were adhered to slides and stained with biotinylated Herceptin and a fluorochrome-conjugated streptavidin (Figure 5 panel D).
  • Herceptin binding to Her2t sensitizes human T cells to ADCC.
  • H9 (T cells) cells (5xl0 6 parental, Her2t + , EGFRt + , or Her2t + /EGFRt + ) were mixed together and then subjected to purification. (Figure 6).
  • the cells were initially purified based on biotinylated Herceptin and anti-biotin multisort beads.
  • the multisort beads were then removed and the positive fraction subsequently subjected to purification based on Erbitux-APC and anti-APC microbeads.
  • the final positive fraction was dual positive for Her2t and EGFRt.( Figure 6).
  • stimulated PBMCs will act as a source of effectors able to induce antibody dependent cellular cytotoxicity in the presence of antibody.
  • the goal would be to selectively eliminate Her2t + or EGFRt + cells when Herceptin or Erbitux is added to the co-culture, respectively.
  • These tests will be expanded in vivo using ffluc + Tcm that co- express Her2t or EGFRt.
  • Tcm will be engrafted into NOD/Scid IL-2RyC nu11 mice followed by the administration of Herceptin or Erbitux and freshly activated PBMCs.
  • the in vivo engraftment and antibody-mediated elimination of transferred Tcm will be measured by in vivo biophotonic imaging.
  • Herceptin or Erbitux-mediated elimination should be specific to Tcm expressing Her2t, EGFRt or both markers.
  • K562 ffluc + tumor cells that are CD19 + , CD20 + or CD19/CD20 + will be established by s.c. injection into the left or right flank of NOD/Scid IL-2RyC nu11 mice.
  • CD 19C AR-Her2t, CD 19C AR-EGFRt, CD20CAR-EGFRt or CD 19C AR-Her2t and CD20CAR expressing Tcm will be injected intravenously following tumor establishment and T cell specificity will be determined by biophotonic imaging. Loss of tumor luciferase activity (total photon flux) will indicate tumor regression.
  • Tumor regression should occur for all tumor targets when mice are treated with the dual CAR-expressing Tcm, while only CD 19 or CD20-expressing K562 tumors should regress when mice are treated with Tcm expressing their cognate CAR.
  • CD19 + , CD20 + or CD19/CD20 + K562 cells will be established as before and ffluc + CAR + Tcm will be administered post tumor establishment.
  • Tcm localization based on CAR- specificity will be determined by biophotonic imaging.
  • the dual-selected Her2t + EGFRt + T cells should localize to both flanks irrespective of target antigen on the K562 tumors, while CD 19 or CD20CAR expressing cells should localized to their target antigen specific K562 tumor.
  • Her2tG linker domain
  • Her2tG differs from Her2t with the addition of a linker sequence between the Her2 domain IV and the transmembrane region and comprises the sequence GGGSGGGS (SEQ ID NO: 45) and the construct is designated as Her2tG.
  • H9 cells were transduced with lentivirus at an MOI of 1 with Her2t or Her2tG. Transduced cells were then purified by biotinylated Herceptin and anti-biotin microbeads according to the manufacturers' protocol. The purified populations were later stained for Her2t or Her2tG using biotinylated Herceptin and streptavidin-PE.
  • H9 cells were transduced with lentivirus at 0.05, 0.1 , 0.25, 0.5, 1 and 3ul (left to right) and then analyzed for Herceptin binding five days later.
  • the Her2t variant Her2t(CD28hinge) was able to bind Herceptin at levels similar to the original Her2t (Her2t staining not shown but based on prior experience).
  • Her2t(IgG4hinge) enhanced Herceptin binding relative to Her2t or Her2t(CD28hinge), while the Her2tG variant had the greatest capacity to bind Herceptin and stain transduced H9 cells.
  • a linker (SEQ ID NO: 45) between Domain IV and the transmembrane domain of Her2t led to the construct Her2tG.
  • the linker is used to induce flexibility between protein domains.
  • the scFv of many CARs contain four consecutive G3S subunits placed between the Vh and VI domains of the CAR's SCFV. This allows for flexibility in folding of the two scFv domains.
  • the rational here is that two G3S linker subunits would suffice in being able to induce the same amount of flexibility for Her2tG.
  • Two G3S linker subunits (SEQ ID NO: 45) was also used to mimic the spacer length of the CD28hinge and IgG4hinge. Both the CD28hinge and IgG4hinge have been used as spacers between the scFv and transmembrane region in CARs that are functional. Both the CD28hinge and IgG4hinge contain a cysteine that help in dimerization. While helpful for CARs, this dimerization may inhibit the flexibility of Her2t and therefore not allow for as significant recognition to Herceptin.
  • the advantage of using two G3S linkers (SEQ ID NO: 45) over three or four was to limit vector payload, eliminate potentially unnecessary sequences and at the same time achieve enhanced functionality.
  • Her2t can be expressed alone or coordinately incorporated into self-inactivating lentiviral vectors alongside biologically active transgenes, namely a chimeric antigen receptor (CAR). Coordinate transgene expression levels were attained by appending Her2t to the CAR via a T2A ribosomal skip linker and were verified by flow and western blot analysis of Her2t- purified CD8 central memory T cells. Furthermore, it was also demonstrated that Her2t is a highly stringent selection epitope that, in comparison to EGFRt selection strategies, allows for the ex vivo selection of T cells with greater CAR expression and effector cytokine production. This characteristic can be advantageous when higher transgene expression levels are desired, as can be the case when expanding CAR therapy to the treatment of multiple tumor types.
  • CAR chimeric antigen receptor
  • Her2t is a complementary selection epitope to EGFRt that, when each selection epitope is appended to a CAR, can facilitate the multisort purification of dual-CAR expressing T cells. Similar cytotoxic activity and effector cytokine production between single and dual-CAR expressing T cells demonstrate that the individual or concerted expression of Her2t and EGFRt does not result in any overt functional impairment.
  • Herceptin is amenable to biotinylation or chemical conjugation. As formulated for commercial use, Herceptin is reconstituted in clinical grade H 2 0 and retains Her2-specific high affinity binding post biotinylation. This, combined with the availability of cGMP grade anti-biotin microbeads (Miltenyi Biotec), enables the selection of therapeutically relevant Her2t + cells on a CliniMACS device. It was demonstrated that cells as low as 13.8% positive for Her2t can be immunomagnetically enriched to >90% purity. Furthermore, the results demonstrate that biotinylated Herceptin can be coupled with antibodies targeted against T cell markers to permit multiparameter phenotypic analysis and track the in vivo distribution of therapeutic, CAR expressing T cells.
  • Her2t An advantage of using Her2t is for its diminutive size. As such Her2t has the advantage of packing efficiency with even bigger constructs. In order to take advantage of the system it is preferred to have the construct less than 5kb. In some alternatives, the size of the construct is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14.9 Kb, or any size in between any two of the construct size listed. The low size is necessary as constructs above 15kb may run the risk of having low titers.
  • GTG AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATG
  • VYMIMVKCWM I DSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL 1000
  • CD20 scFV Protein (SEQ ID NO: 25)
  • CD20CAR construct CD28tm-41BB-zeta-T2A-EGFRt
  • CD19CAR-T2A-EGFRt construct CD19CAR-T2A-EGFRt construct.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
PCT/US2015/024895 2014-04-10 2015-04-08 Transgene genetic tags and methods of use Ceased WO2015157399A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
EP21180797.9A EP3954708A1 (en) 2014-04-10 2015-04-08 Transgene genetic tags and methods of use
PH1/2016/502011A PH12016502011B1 (en) 2014-04-10 2015-04-08 Transgene genetic tags and methods of use
EP15776745.0A EP3129405B1 (en) 2014-04-10 2015-04-08 Transgene genetic tags and methods of use
BR112016023507-0A BR112016023507B1 (pt) 2014-04-10 2015-04-08 Polipeptídeo isolado que compreende um domínio extracelular de um polipeptídeo her2
JP2016561722A JP6772068B2 (ja) 2014-04-10 2015-04-08 導入遺伝子の遺伝子タグおよびその使用方法
KR1020167031068A KR102387243B1 (ko) 2014-04-10 2015-04-08 트랜스진 유전자 태그 및 사용 방법
US15/302,420 US10611837B2 (en) 2014-04-10 2015-04-08 Transgene genetic tags and methods of use
AU2015243849A AU2015243849B2 (en) 2014-04-10 2015-04-08 Transgene genetic tags and methods of use
MYPI2016703721A MY184163A (en) 2014-04-10 2015-04-08 Transgene genetic tags and methods of use
SG11201608393TA SG11201608393TA (en) 2014-04-10 2015-04-08 Transgene genetic tags and methods of use
RU2016143384A RU2729112C2 (ru) 2014-04-10 2015-04-08 Трансгенные генетические метки и способы применения
KR1020227011931A KR102600544B1 (ko) 2014-04-10 2015-04-08 트랜스진 유전자 태그 및 사용 방법
ES15776745T ES2867224T3 (es) 2014-04-10 2015-04-08 Etiquetas genéticas transgénicas y métodos de uso
CA2945308A CA2945308C (en) 2014-04-10 2015-04-08 Transgene genetic tags and methods of use
CN201580030814.2A CN106536558A (zh) 2014-04-10 2015-04-08 转基因遗传标签和使用的方法
NZ725079A NZ725079A (en) 2014-04-10 2015-04-08 Transgene genetic tags and methods of use
IL248238A IL248238B2 (en) 2014-04-10 2015-04-08 Transgenic genetic markers and methods of use
MX2016013160A MX387465B (es) 2014-04-10 2015-04-08 Marcas genéticas de transgenes y métodos de uso.
ZA2016/07061A ZA201607061B (en) 2014-04-10 2016-10-13 Transgene genetic tags and methods of use
US16/794,673 US11414486B2 (en) 2014-04-10 2020-02-19 Transgene genetic tags and methods of use
AU2021201679A AU2021201679B2 (en) 2014-04-10 2021-03-17 Transgene genetic tags and methods of use
US17/812,848 US12448445B2 (en) 2014-04-10 2022-07-15 Transgene genetic tags and methods of use

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201461977751P 2014-04-10 2014-04-10
US61/977,751 2014-04-10
US201461986479P 2014-04-30 2014-04-30
US61/986,479 2014-04-30
US201462058973P 2014-10-02 2014-10-02
US62/058,973 2014-10-02
US201462088363P 2014-12-05 2014-12-05
US62/088,363 2014-12-05
US201462089730P 2014-12-09 2014-12-09
US62/089,730 2014-12-09
US201462090845P 2014-12-11 2014-12-11
US62/090,845 2014-12-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/302,420 A-371-Of-International US10611837B2 (en) 2014-04-10 2015-04-08 Transgene genetic tags and methods of use
US16/794,673 Division US11414486B2 (en) 2014-04-10 2020-02-19 Transgene genetic tags and methods of use

Publications (2)

Publication Number Publication Date
WO2015157399A1 true WO2015157399A1 (en) 2015-10-15
WO2015157399A9 WO2015157399A9 (en) 2016-11-24

Family

ID=54288361

Family Applications (5)

Application Number Title Priority Date Filing Date
PCT/US2015/024895 Ceased WO2015157399A1 (en) 2014-04-10 2015-04-08 Transgene genetic tags and methods of use
PCT/US2015/024866 Ceased WO2015157384A1 (en) 2014-04-10 2015-04-08 Defined composition gene modified t-cell products
PCT/US2015/024868 Ceased WO2015157386A1 (en) 2014-04-10 2015-04-08 Production of engineered t-cells by sleeping beauty transposon coupled with methotrexate selection
PCT/US2015/024947 Ceased WO2015157432A1 (en) 2014-04-10 2015-04-08 Drug related transgene expression
PCT/US2015/024882 Ceased WO2015157391A1 (en) 2014-04-10 2015-04-08 Method and compositions for cellular immunotherapy

Family Applications After (4)

Application Number Title Priority Date Filing Date
PCT/US2015/024866 Ceased WO2015157384A1 (en) 2014-04-10 2015-04-08 Defined composition gene modified t-cell products
PCT/US2015/024868 Ceased WO2015157386A1 (en) 2014-04-10 2015-04-08 Production of engineered t-cells by sleeping beauty transposon coupled with methotrexate selection
PCT/US2015/024947 Ceased WO2015157432A1 (en) 2014-04-10 2015-04-08 Drug related transgene expression
PCT/US2015/024882 Ceased WO2015157391A1 (en) 2014-04-10 2015-04-08 Method and compositions for cellular immunotherapy

Country Status (19)

Country Link
US (11) US20170029774A1 (enExample)
EP (8) EP3129471A4 (enExample)
JP (12) JP6788573B6 (enExample)
KR (8) KR102618955B1 (enExample)
CN (7) CN106661570B (enExample)
AU (8) AU2015243849B2 (enExample)
BR (3) BR112016023517A2 (enExample)
CA (5) CA2945305C (enExample)
ES (2) ES2867224T3 (enExample)
IL (5) IL248238B2 (enExample)
MX (6) MX2016013158A (enExample)
MY (4) MY186846A (enExample)
NZ (3) NZ725079A (enExample)
PH (4) PH12016502010B1 (enExample)
RU (5) RU2751921C2 (enExample)
SA (1) SA516380056B1 (enExample)
SG (8) SG11201608393TA (enExample)
WO (5) WO2015157399A1 (enExample)
ZA (3) ZA201607061B (enExample)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079703A1 (en) * 2015-11-05 2017-05-11 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
WO2017112877A1 (en) * 2015-12-22 2017-06-29 Icell Gene Therapeutics, Llc Chimeric antigen receptors and enhancement of anti-tumor activity
WO2017211900A1 (en) * 2016-06-07 2017-12-14 Max-Delbrück-Centrum für Molekulare Medizin Chimeric antigen receptor and car-t cells that bind bcma
WO2018075941A1 (en) * 2016-10-21 2018-04-26 Washington University Ap4 and methods of promoting t cell activation
EP3331920A4 (en) * 2015-08-07 2019-04-03 Seattle Children's Hospital, dba Seattle Children's Research Institute BIS SPECIFIC CAR T CELLS FOR TARGETING OF SOLID TUMORS
US10273280B2 (en) 2015-02-27 2019-04-30 Icell Gene Therapeutics Llc Chimeric antigen receptors (CARs), targeting hematologic malignancies, compositions and methods of use thereof
JP2020505034A (ja) * 2017-01-20 2020-02-20 ジュノ セラピューティクス ゲーエムベーハー 細胞表面コンジュゲートならびに関連する細胞組成物および方法
US10611837B2 (en) 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
EP3359574B1 (en) * 2015-10-06 2020-04-22 City of Hope Chimeric antigen receptors targeted to psca
US10758556B2 (en) 2017-08-07 2020-09-01 Nbe-Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
EP3858378A1 (en) * 2013-11-21 2021-08-04 Autolus Limited Cell
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
US11896615B2 (en) 2016-10-13 2024-02-13 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
US11919970B2 (en) 2015-01-16 2024-03-05 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ROR1
US12208137B2 (en) 2014-04-23 2025-01-28 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
US12268741B2 (en) 2019-01-29 2025-04-08 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)
US12275787B2 (en) 2017-06-21 2025-04-15 Icell Gene Therapeutics Llc Chimeric antigen receptors (CARs), compositions and methods thereof
EP4491715A3 (en) * 2015-04-08 2025-06-18 Novartis AG Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
US12491153B2 (en) 2018-01-03 2025-12-09 Qu Biologics Inc. Innate targeting of adoptive cellular therapies

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100548667C (zh) * 2003-01-20 2009-10-14 日本瑞翁株式会社 层合件及其制造方法
US20150320799A1 (en) 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
WO2015167766A1 (en) 2014-04-29 2015-11-05 Seattle Children's Hospital (dba Seattle Children's Research Institute) Ccr5 disruption of cells expressing anti-hiv chimeric antigen receptor (car) derived from broadly neutralizing antibodies
SG10202104804PA (en) 2014-10-20 2021-06-29 Juno Therapeutics Inc Methods and compositions for dosing in adoptive cell therapy
EP4427809A3 (en) 2014-10-31 2024-12-04 The Trustees of The University of Pennsylvania Altering gene expression in car-t cells and uses thereof
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
EP3227323B1 (en) 2014-12-03 2020-08-05 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
DK3226897T3 (da) 2014-12-05 2021-04-19 Memorial Sloan Kettering Cancer Center Antistoffer der rammer b-cellemodningsantigen og fremgangsmåder til anvendelse
US11253546B2 (en) 2014-12-15 2022-02-22 The Regents Of The University Of California Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
WO2016138091A2 (en) * 2015-02-24 2016-09-01 Board Of Regents, The University Of Texas System Selection methods for genetically-modified t cells
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
US11655452B2 (en) 2015-06-25 2023-05-23 Icell Gene Therapeutics Inc. Chimeric antigen receptors (CARs), compositions and methods of use thereof
AU2016325384B2 (en) * 2015-09-22 2021-07-22 Julius-Maximilians-Universitat Wurzburg A method for high level and stable gene transfer in lymphocytes
US20180311331A1 (en) * 2015-10-23 2018-11-01 The Regents Of The University Of Colorado, A Body Corporate Prognosis and treatment of squamous cell carcinomas
EP3368574A1 (en) 2015-10-30 2018-09-05 NBE-Therapeutics AG Anti-ror1 antibodies
CN108603200B (zh) * 2015-11-23 2022-08-19 诺华股份有限公司 优化的慢病毒转移载体及其用途
NZ742068A (en) * 2015-12-14 2023-07-28 Genomefrontier Therapeutics Inc Transposon system, kit comprising the same, and uses thereof
CN108848669B (zh) 2016-01-20 2022-06-07 斯克利普斯研究所 Ror1抗体组合物和相关方法
EP3202783A1 (en) * 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
EP3430549A1 (en) 2016-03-16 2019-01-23 Juno Therapeutics, Inc. Methods for adaptive design of a treatment regimen and related treatments
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
WO2017190100A1 (en) * 2016-04-28 2017-11-02 The Trustees Of Dartmouth College Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
US11787848B2 (en) * 2016-06-08 2023-10-17 Precigen, Inc. CD33 specific chimeric antigen receptors
EP4353750A3 (en) * 2016-06-24 2024-07-24 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars), compositions and methods thereof
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
WO2018102606A1 (en) * 2016-11-30 2018-06-07 Intrexon Corporation Steroid administration and immunotherapy
MA46995A (fr) 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
CN106800601B (zh) * 2017-01-19 2021-04-06 广东昭泰体内生物医药科技有限公司 一种嵌合抗原受体及其应用
CA3053539A1 (en) 2017-02-27 2018-08-30 Juno Therapeutics, Inc. Compositions, articles of manufacture and methods related to dosing in cell therapy
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
EP3595440A2 (en) 2017-03-14 2020-01-22 Juno Therapeutics, Inc. Methods for cryogenic storage
CN106963945A (zh) * 2017-03-27 2017-07-21 山东兴瑞生物科技有限公司 一种加强型人乳头瘤病毒hpv‑16/18的二价dc疫苗
WO2018191490A1 (en) * 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN108728477B (zh) * 2017-04-24 2022-02-22 华东理工大学 一种高效的转座突变系统及构建方法
WO2018213332A1 (en) * 2017-05-17 2018-11-22 Seattle Children's Hospital (dba Seattle Children's Research Institute) Generating mammalian t cell activation inducible synthetic promoters (syn+pro) to improve t cell therapy
US10780119B2 (en) 2017-05-24 2020-09-22 Effector Therapeutics Inc. Methods and compositions for cellular immunotherapy
CN110662834B (zh) * 2017-05-26 2023-09-12 Gc细胞治疗 使用转化的t细胞培养自然杀伤细胞的方法
KR20200054160A (ko) 2017-06-02 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
CN107335054B (zh) * 2017-06-30 2021-01-15 山东兴瑞生物科技有限公司 一种慢性乙肝治疗性dc疫苗
CA3072569A1 (en) * 2017-08-11 2019-02-14 Tribiotica Llc Methods for generating epitopes for binding to recognition molecules by templated assembly
WO2019038368A1 (en) * 2017-08-23 2019-02-28 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft CHIMERIC ANTIGEN RECEPTOR AND CAR CXCR5 BINDING T CARRIER
KR20200070236A (ko) * 2017-09-26 2020-06-17 롱우드 유니버시티 면역치료제로서의 pd1-특이적 키메라 항원 수용체
AU2018352984B2 (en) 2017-10-18 2024-02-01 Precigen, Inc. Polypeptide compositions comprising spacers
CN107759700A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd19抗原的转基因t细胞及其制备方法与应用
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
CA3080904A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
BR112020008638A2 (pt) 2017-11-01 2020-10-20 Juno Therapeutics Inc receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
WO2019089855A1 (en) * 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
AU2018359907A1 (en) 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
KR20250143360A (ko) 2017-11-10 2025-10-01 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 종양 항원을 타겟으로 하는 키메릭 항원 수용체
EP3710020A4 (en) * 2017-11-14 2021-06-23 Memorial Sloan-Kettering Cancer Center IL-36 SECRECTING IMMUNOREACTIVE CELLS AND RELATED USES
US12161670B2 (en) 2017-12-08 2024-12-10 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US10561686B2 (en) 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
CN110028588A (zh) * 2018-01-11 2019-07-19 上海细胞治疗研究院 抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用
AU2019209432A1 (en) 2018-01-22 2020-08-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for CAR T cells
CN108103027B (zh) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） 高效率血细胞重编程同时实现基因编辑的方法
JP7062792B2 (ja) 2018-02-13 2022-05-06 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
CN108383914A (zh) 2018-02-23 2018-08-10 北京美康基免生物科技有限公司 一种基于cd19的嵌合抗原受体及其应用
JP2021515576A (ja) * 2018-03-16 2021-06-24 イミュソフト コーポレーション フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法
KR20200138741A (ko) 2018-04-02 2020-12-10 내셔널 유니버시티 오브 싱가포르 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
EP3781556B1 (en) 2018-04-19 2025-06-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
KR102732008B1 (ko) 2018-05-14 2024-11-20 길리애드 사이언시즈, 인코포레이티드 Mcl-1 억제제
WO2019219029A1 (zh) * 2018-05-15 2019-11-21 科济生物医药（上海）有限公司 基因工程化的细胞及应用
MX2020013923A (es) 2018-06-29 2021-03-29 Apitbio Inc Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
CN118221646A (zh) 2018-07-13 2024-06-21 吉利德科学公司 Pd-1/pd-l1抑制剂
CN110845621A (zh) * 2018-08-21 2020-02-28 上海恒润达生生物科技有限公司 一种靶向egfr和cd19双靶点的嵌合抗原受体方法
JP7560882B2 (ja) * 2018-08-29 2024-10-03 ナショナル ユニヴァーシティー オブ シンガポール 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
CA3110858A1 (en) * 2018-08-31 2020-03-05 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods and compositions comprising b7h3 chimeric antigen receptors
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
WO2020080908A1 (ko) * 2018-10-19 2020-04-23 주식회사 헬릭스미스 항-l1cam 항체 또는 그의 항원결합 단편, 및 이를 포함하는 키메라 항원 수용체
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
MX2021005047A (es) 2018-10-31 2021-09-08 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
AU2019372673A1 (en) 2018-11-01 2021-05-27 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for T cell engineering
EP3892721A4 (en) 2018-11-14 2022-08-31 GC Cell Corporation METHOD FOR CULTIVATING NATURAL KILLER CELLS DERIVED FROM UMBILICAL CORD BLOOD USING TRANSFORMED T LYMPHOCYTES
CA3120118A1 (en) * 2018-11-16 2020-05-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
WO2020113194A2 (en) * 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
WO2020113234A1 (en) * 2018-11-30 2020-06-04 Celularity, Inc. Placenta-derived allogeneic car-t cells and uses thereof
IL283298B2 (en) * 2018-11-30 2025-03-01 Juno Therapeutics Inc Methods for dosing and treating B-cell malignancies with adoptive cell therapy
US20220042038A1 (en) * 2018-12-20 2022-02-10 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
AU2020231115B2 (en) 2019-03-07 2025-02-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
DK3934757T3 (da) 2019-03-07 2023-04-17 Inst Of Organic Chemistry And Biochemistry Ascr V V I 2'3'-cykliske dinukleotider og prodrugs deraf
US20200297768A1 (en) * 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
US20200308248A1 (en) * 2019-03-26 2020-10-01 ST Phi Therapeutics Chimeric Natural Killer Cell Receptors and Method of Using Thereof
WO2020210023A1 (en) * 2019-04-08 2020-10-15 Russell Biotech, Inc. Improved manufacturing procedures for cell based therapies
CN109994176A (zh) * 2019-04-16 2019-07-09 北京中佰耀因医药科技有限公司 一种含样本类型信息管理模块的精准用药智能报告系统
CN109994156A (zh) * 2019-04-16 2019-07-09 北京中佰耀因医药科技有限公司 一种含报告模板信息管理模块的精准用药智能报告系统
CN109872792A (zh) * 2019-04-16 2019-06-11 北京中佰耀因医药科技有限公司 一种用于指导精准用药的基因检测智能报告系统
CN109979545A (zh) * 2019-04-16 2019-07-05 北京中佰耀因医药科技有限公司 一种含样本状态信息管理模块的精准用药智能报告系统
CN110010222A (zh) * 2019-04-16 2019-07-12 长沙三济生物科技有限公司 一种基于精准用药知识库的基因身份识别系统
CN109994180A (zh) * 2019-04-16 2019-07-09 北京中佰耀因医药科技有限公司 一种含基因位点信息管理模块的精准用药智能报告系统
CN110010200A (zh) * 2019-04-16 2019-07-12 长沙三济生物科技有限公司 一种基因身份识别系统
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
WO2020247837A1 (en) * 2019-06-07 2020-12-10 The Trustees Of The University Of Pennsylvania Dual car expressing t cells individually linked to cd28 and 4-1bb
AU2020294700A1 (en) * 2019-06-17 2022-02-03 Renovaro Biosciences Inc. Allogeneic T-cell-based HIV vaccine to induce cellular and humoral immunity
CN114222763A (zh) * 2019-06-19 2022-03-22 尤利乌斯·马克西米利安维尔茨堡大学 在嵌合抗原受体设计中实现的超模块化IgG3间隔区结构域和多功能位点
PE20220231A1 (es) 2019-06-25 2022-02-07 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso
CN110608991B (zh) * 2019-09-09 2022-04-29 浙江普罗亭健康科技有限公司 基于质谱流式检测技术的细胞周期检测试剂盒及检测方法
US11795223B2 (en) 2019-10-18 2023-10-24 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
MX2022005123A (es) 2019-10-31 2022-05-30 Forty Seven Inc Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico.
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
MX2022007930A (es) 2019-12-24 2022-08-08 Carna Biosciences Inc Compuestos moduladores de diacilglicerol quinasa.
BR112022014623A2 (pt) 2020-02-14 2022-09-13 Jounce Therapeutics Inc Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
CN111533808B (zh) * 2020-03-10 2021-02-09 南京医科大学 一种可自分泌TLR4 scFv且靶向cMet的嵌合抗原受体修饰的T细胞及其应用
IL296511A (en) 2020-03-20 2022-11-01 Lyell Immunopharma Inc Novel recombinant cell surface markers
US20240043427A1 (en) 2020-05-01 2024-02-08 Gilead Sciences, Inc. Cd73 compounds
GB202007169D0 (en) * 2020-05-14 2020-07-01 Ospedale San Raffaele Srl Epidermal growth factor receptor
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
IL298779A (en) * 2020-06-08 2023-02-01 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Anti-cd171 chimeric antigen receptors
CN115701999A (zh) * 2020-07-09 2023-02-14 南京传奇生物科技有限公司 用白介素-36工程化γδT细胞用于免疫疗法
US20230310606A1 (en) 2020-07-17 2023-10-05 Simurx, Inc. Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
AU2021397206A1 (en) * 2020-12-08 2023-07-27 Seattle Children's Hospital (dba Seattle Children's Research Institute) Anti-egfr chimeric antigen receptors
EP4277639A4 (en) * 2021-01-15 2025-03-05 Seattle Children's Hospital d/b/a Seattle Children's Research Institute HYBRID AND TRUNCATED IMMUNE CELL PROTEINS
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
JP7686086B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN118056012B (zh) * 2021-08-24 2025-05-30 赛斯尔擎生物技术（上海）有限公司 一种修饰细胞的方法
CA3232968A1 (en) 2021-10-14 2023-04-20 Jasper Williams Immune cells having co-expressed shrnas and logic gate systems
AU2022375782A1 (en) 2021-10-28 2024-05-02 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US20250228940A1 (en) * 2022-03-11 2025-07-17 Yale University Compositions and methods for efficient and stable genetic modification of eukaryotic cells
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
JP2025509662A (ja) 2022-03-24 2025-04-11 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
CN118973608A (zh) * 2022-04-01 2024-11-15 美天施生物科技有限两合公司 用于多核苷酸的药物诱导型表达的系统
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
EP4514834A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
JP2025516189A (ja) 2022-04-28 2025-05-27 イマティクス ユーエス，アイエヌシー． 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法
CN114990069B (zh) * 2022-05-17 2023-09-22 郑州大学第一附属医院 一种过表达slc43a2的嵌合抗原受体t细胞的制备方法和应用
JP2025517516A (ja) * 2022-05-27 2025-06-05 オートラス リミテッド 方法
AR129552A1 (es) * 2022-06-10 2024-09-04 Joint Stock Company “Biocad” Ácido nucleico con actividad promotora y uso del mismo
WO2024006702A1 (en) * 2022-06-27 2024-01-04 Foundation Medicine, Inc. Methods and systems for predicting genotypic calls from whole-slide images
CA3260083A1 (en) 2022-07-01 2024-01-04 Gilead Sciences Inc CD73 COMPOUNDS
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
CN116179495B (zh) * 2022-11-28 2025-06-06 上海恩凯细胞技术有限公司 转基因免疫细胞及其应用
EP4633649A1 (en) * 2022-12-15 2025-10-22 The Board of Trustees of the Leland Stanford Junior University Homology-independent targeted dna insertion in human t cells
AU2023408894A1 (en) * 2022-12-20 2025-06-12 Abata Therapeutics, Inc. Cell therapies for type 1 diabetes
US20240254118A1 (en) 2022-12-22 2024-08-01 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024153036A1 (zh) * 2023-01-19 2024-07-25 武汉昭智生物技术有限公司 一种car分子、包含其的细胞或外泌体及它们的应用
US20240290628A1 (en) * 2023-02-24 2024-08-29 American Air Liquide, Inc. Etching method using oxygen-containing hydrofluorocarbon
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向ｐｓｍａ及ｃａ９之系統
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
CN121079300A (zh) 2023-04-21 2025-12-05 吉利德科学公司 Prmt5抑制剂及其用途
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
CN116844685B (zh) * 2023-07-03 2024-04-12 广州默锐医药科技有限公司 一种免疫治疗效果评估方法、装置、电子设备及存储介质
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025207642A1 (en) * 2024-03-25 2025-10-02 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Cxcr3 isoforms to improve recombinant receptor trafficking
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018923A1 (en) * 1996-10-25 1998-05-07 G.D. Searle & Co. NOVEL flt-3 RECEPTOR AGONISTS
WO2003025228A1 (en) * 2001-09-18 2003-03-27 Proteologics, Inc. Methods and compositions for treating hcap associated diseases
WO2005017102A2 (en) 2003-05-30 2005-02-24 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
WO2010141543A1 (en) 2009-06-02 2010-12-09 Targeted Molecular Diagnostics, Llc Methods for the detection and quantitation of the p95 component of her2/neu (erbb2)

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0557459B1 (en) 1990-11-13 1997-10-22 Immunex Corporation Bifunctional selectable fusion genes
US20020111474A1 (en) 1990-12-14 2002-08-15 Capon Daniel J. Chimeric chains for receptor-associated signal transduction pathways
WO1994000143A1 (en) 1992-06-01 1994-01-06 New England Medical Center Hospitals, Inc. Blocking intercellular interactions with cd43 chimeric molecules
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6133027A (en) * 1996-08-07 2000-10-17 City Of Hope Inducible expression system
AU2472400A (en) * 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20040037816A1 (en) 1999-04-15 2004-02-26 Monash University Graft acceptance through manipulation of thymic regeneration
US6912492B1 (en) * 1999-05-25 2005-06-28 University Of Medicine & Dentistry Of New Jersey Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
JP4045713B2 (ja) 2000-01-31 2008-02-13 松下電器産業株式会社 自動機用溶接機
GB0015119D0 (en) * 2000-06-20 2000-08-09 Angeletti P Ist Richerche Bio Methods and means for regulation of gene expression
EP1297168A2 (en) * 2000-07-03 2003-04-02 Gala Design, Inc. Expression vectors
GB0025307D0 (en) * 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
EP1334188B1 (en) 2000-11-07 2006-08-30 City of Hope Cd19-specific redirected immune cells
BR0207854A (pt) 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
WO2002097099A1 (en) 2001-05-29 2002-12-05 Valentis, Inc. Regulated expression of ghrh
EP1397382B1 (en) 2001-05-31 2008-08-06 Novartis AG Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
MXPA04009809A (es) 2002-04-11 2004-12-13 Amgen Inc Moleculas de tirosina cinasa del receptor her-2 y uso de las mismas.
US20040115814A1 (en) 2002-09-30 2004-06-17 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
WO2004073656A2 (en) 2003-02-20 2004-09-02 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20050129671A1 (en) * 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US20060160090A1 (en) 2003-04-11 2006-07-20 Macina Robert A Composition splice variants and methods relating to cancer specific genes and proteins
ZA200509363B (en) * 2003-04-18 2007-04-25 Norwood Immunology Ltd Tolerance to graft prior to thymic regeneration
JP4772674B2 (ja) 2003-07-21 2011-09-14 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ヒト上皮成長因子２／ｎｅｕ抗原をコードする合成遺伝子およびその用途
WO2005040212A2 (en) * 2003-10-24 2005-05-06 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Orthogonal gene switches
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
WO2005062881A2 (en) 2003-12-24 2005-07-14 Transgenrx, Inc. Gene therapy using transposon-based vectors
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7910101B2 (en) * 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
DE202005002921U1 (de) 2005-02-23 2005-04-21 Magcode Ag Verbindungssystem, insbesondere elektrisches Verbindungssystem
JP2008541764A (ja) 2005-06-01 2008-11-27 バイオテック・インスティチュート・フォー・インターナショナル・イノベーション・インコーポレーテッド グルコース誘導性のインシュリンの発現及び糖尿病を治療する方法
KR20080090441A (ko) 2005-12-21 2008-10-08 메디뮨 엘엘씨 Ｅｐｈａ２ ｂｉｔｅ 분자 및 이의 용도
BRPI0711207A2 (pt) 2006-05-22 2011-03-22 Hiprocell Llc vetor alvo para intregação em sìtios-especificos, método de sìtio-especìfico que integra um polinucleotìdeo codificando uma proteina de interesse em um genoma de uma célula eucariótia, célula eucariótica isolada , kit para uso no sìtio-especìfico que integra um polinucleotideo dentro de um genoma de uma celula in vitro e kit para uso em produzir uma proteìna em célula
US8148129B2 (en) 2006-06-30 2012-04-03 The Regents Of The University Of California Generation of potent dominant negative transcriptional inhibitors
WO2008012237A1 (en) 2006-07-24 2008-01-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Multi-antigen construct and uses thereof
US7709253B2 (en) * 2006-08-04 2010-05-04 The Board Of Trustees Of The Leland Stanford Junior University Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists
CA2693155A1 (en) * 2007-07-25 2009-01-29 Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Self coupling recombinant antibody fusion proteins
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
DK2279253T3 (en) * 2008-04-09 2017-02-13 Maxcyte Inc Construction and application of therapeutic compositions of freshly isolated cells
PL3006459T3 (pl) 2008-08-26 2022-01-17 City Of Hope Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
WO2010036986A2 (en) 2008-09-26 2010-04-01 Tocagen Inc. Recombinant vectors
US8329882B2 (en) * 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
US9873035B2 (en) * 2009-07-09 2018-01-23 Cfph, Llc Amusement device for a game of chance involving one or more rolling indicators on a rotating element with position indicators
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
EP2483301A1 (en) 2009-10-01 2012-08-08 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
ES2911246T3 (es) * 2009-11-03 2022-05-18 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas
JP5285678B2 (ja) 2010-06-18 2013-09-11 株式会社エヌ・ティ・ティ・ドコモ 移動通信方法及びコアネットワーク装置
US9212229B2 (en) 2010-09-08 2015-12-15 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
AU2012207356A1 (en) 2011-01-18 2013-08-01 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
KR101976882B1 (ko) * 2011-03-23 2019-05-09 프레드 헛친슨 켄서 리서치 센터 세포 면역요법용 방법 및 조성물
CN103502439B (zh) * 2011-04-13 2016-10-12 因缪尼卡姆股份公司 用于抗原特异性t细胞增殖的方法
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
DK3489366T3 (da) 2011-06-01 2020-02-24 Prec Biosciences Inc Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener
ES2667864T3 (es) * 2011-06-22 2018-05-14 F. Hoffmann-La Roche Ag Eliminación de células diana mediante linfocitos T citotóxicos específicos de virus en circulación usando complejos que comprenden MHC de clase I
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
DE102011118018B4 (de) 2011-10-25 2017-10-26 Plasmidfactory Gmbh & Co. Kg Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
ITRM20120058A1 (it) 2012-02-20 2013-08-21 Pisanelli Giovanni Codacci Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione
EP2817330B1 (en) * 2012-02-22 2020-07-08 The Trustees of the University of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
WO2013154760A1 (en) 2012-04-11 2013-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
US9540657B2 (en) 2012-05-25 2017-01-10 California Institute Of Technology Expression of secreted and cell-surface polypeptides
KR20150027756A (ko) 2012-05-30 2015-03-12 베일러 칼리지 오브 메디신 Dna 수복, 변경 및 대체를 위한 도구로서의 초나선 미니벡터
EP2669378A1 (en) 2012-05-31 2013-12-04 Helmut Hanenberg Cytochrome P450 suicide gene system
WO2013180287A1 (ja) 2012-06-01 2013-12-05 日本電気株式会社 スイッチングシステム、ラインカード、スイッチカード、ｆｄｂ学習方法、ｆｄｂ学習調停方法及びプログラム
PL2884999T3 (pl) 2012-08-20 2021-07-05 Fred Hutchinson Cancer Research Center Sposób i kompozycje do immunoterapii komórkowej
WO2014039044A1 (en) * 2012-09-06 2014-03-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t memory stem cell populations
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
ES2824024T3 (es) 2012-10-10 2021-05-11 Sangamo Therapeutics Inc Compuestos modificadores de células T y usos de los mismos
US9405601B2 (en) 2012-12-20 2016-08-02 Mitsubishi Electric Corporation In-vehicle apparatus and program
WO2014099671A1 (en) 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
EP2964753B1 (en) 2013-03-07 2018-04-25 Baylor College of Medicine Targeting cd138 in cancer
EP2777711A1 (en) 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
KR102238226B1 (ko) * 2013-05-14 2021-04-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용
WO2014190273A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
AU2014342020C1 (en) * 2013-10-31 2019-09-05 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof
WO2015075468A1 (en) 2013-11-21 2015-05-28 Ucl Business Plc Cell
CN106029087A (zh) 2013-12-20 2016-10-12 印第安纳大学研究及科技有限公司 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽
AU2014368383B2 (en) 2013-12-20 2020-01-16 Cellectis Method of engineering multi-input signal sensitive T cell for immunotherapy
EP3626748A1 (en) 2014-01-13 2020-03-25 Stephen J. Forman Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
CA2931979A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding properties
KR102375998B1 (ko) 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 항원 수용체 및 제조방법
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
SG11201608393TA (en) 2014-04-10 2016-11-29 Seattle Children S Hospital Dba Seattle Children S Res Inst Transgene genetic tags and methods of use
WO2015172339A1 (zh) 2014-05-14 2015-11-19 科济生物医药（上海）有限公司 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞
AU2015270912B9 (en) 2014-06-02 2021-01-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting CD-19
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
CN107106611B (zh) 2014-10-27 2021-11-23 弗雷德哈钦森癌症研究中心 用于提高过继细胞免疫疗法效力的组合物和方法
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
KR20180029201A (ko) 2015-05-18 2018-03-20 티씨알2 테라퓨틱스 인크. 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법
KR20240013282A (ko) 2015-06-10 2024-01-30 이뮤너티바이오, 인크. 암을 치료하기 위한 변형된 nk-92 세포
EP4286511A3 (en) 2015-06-12 2024-03-06 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
AU2017213661B2 (en) 2016-02-05 2022-06-02 City Of Hope Administration of engineered T cells for treatment of cancers in the central nervous system
WO2017172952A1 (en) 2016-04-01 2017-10-05 Promab Biotechnologies, Inc. Flag tagged cd19-car-t cells
PL3518972T3 (pl) 2016-09-28 2025-04-07 Kite Pharma, Inc. Cząsteczki wiążące antygen i sposoby ich zastosowania
JP6887492B6 (ja) 2016-10-04 2021-07-14 プレシジョン バイオサイエンシズ，インク． 遺伝子改変細胞で使用するための共刺激ドメイン
CN110291200B (zh) 2016-12-12 2024-05-14 西雅图儿童医院（Dba西雅图儿童研究所） 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
CN111936518A (zh) 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
CN112789051A (zh) 2018-08-06 2021-05-11 西雅图儿童医院（Dba西雅图儿童研究所） 用半抗原标记的细胞刺激嵌合抗原受体t细胞的方法和组合物
US10714296B2 (en) 2018-12-12 2020-07-14 Axcelis Technologies, Inc. Ion source with tailored extraction shape
US11104732B2 (en) 2019-04-24 2021-08-31 Innovative Cellular Therapeutics Holdings, Ltd. Reducing immune inhibition induced by SIGLEC-15

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018923A1 (en) * 1996-10-25 1998-05-07 G.D. Searle & Co. NOVEL flt-3 RECEPTOR AGONISTS
WO2003025228A1 (en) * 2001-09-18 2003-03-27 Proteologics, Inc. Methods and compositions for treating hcap associated diseases
WO2005017102A2 (en) 2003-05-30 2005-02-24 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
WO2010141543A1 (en) 2009-06-02 2010-12-09 Targeted Molecular Diagnostics, Llc Methods for the detection and quantitation of the p95 component of her2/neu (erbb2)

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALTSCHUL ET AL., METHODS IN ENZYMOLOGY, vol. 266, 1996, pages 460 - 480
BEJCEK ET AL., CANCER RES, 2005
CHO ET AL., NATURE, vol. 421, 2003, pages 756
GARRETT ET AL., J. IMMUNOLOGY, vol. 178, 2007, pages 7120
GARRETT, J ET AL.: "Novel Engineered Trastuzumab Conformational Epitopes Demonstrate In Vitro And In Vivo Antitumor Properties Against HER-2/neu.", THE JOURNAL OF IMMUNOLOGY, vol. 178, 2007, pages 7120 - 7131, XP055230038 *
J. T. GARRETT ET AL., J. IMMUNOL., vol. 178, 2007, pages 7120 - 7131
PEZUTTO ET AL., JI, 1987
X. WANG ET AL., BLOOD, vol. 118, 2011, pages 1255 - 1263

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3858378A1 (en) * 2013-11-21 2021-08-04 Autolus Limited Cell
US12202897B2 (en) 2014-04-10 2025-01-21 Seattle Children's Hospital Drug regulated transgene expression
US11414486B2 (en) 2014-04-10 2022-08-16 Seattle Children's Hospital Transgene genetic tags and methods of use
US12258397B2 (en) 2014-04-10 2025-03-25 Seattle Children's Hospital Production of engineered T-cells by sleeping beauty transposon coupled with methotrexate selection
US10611837B2 (en) 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
US12448445B2 (en) 2014-04-10 2025-10-21 Seattle Children's Hospital Transgene genetic tags and methods of use
US10865242B2 (en) 2014-04-10 2020-12-15 Seattle Children's Hospital Method and compositions for cellular immunotherapy
US11155616B2 (en) 2014-04-10 2021-10-26 Seattle Children's Hospital Drug regulated transgene expression
US12296010B2 (en) 2014-04-23 2025-05-13 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
US12208137B2 (en) 2014-04-23 2025-01-28 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
US11919970B2 (en) 2015-01-16 2024-03-05 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ROR1
US10273280B2 (en) 2015-02-27 2019-04-30 Icell Gene Therapeutics Llc Chimeric antigen receptors (CARs), targeting hematologic malignancies, compositions and methods of use thereof
EP4491715A3 (en) * 2015-04-08 2025-06-18 Novartis AG Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
EP3331920A4 (en) * 2015-08-07 2019-04-03 Seattle Children's Hospital, dba Seattle Children's Research Institute BIS SPECIFIC CAR T CELLS FOR TARGETING OF SOLID TUMORS
US11123369B2 (en) 2015-08-07 2021-09-21 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
US11466097B2 (en) 2015-10-06 2022-10-11 City Of Hope Chimeric antigen receptors targeted to PSCA
EP3359574B1 (en) * 2015-10-06 2020-04-22 City of Hope Chimeric antigen receptors targeted to psca
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
WO2017079703A1 (en) * 2015-11-05 2017-05-11 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
WO2017112877A1 (en) * 2015-12-22 2017-06-29 Icell Gene Therapeutics, Llc Chimeric antigen receptors and enhancement of anti-tumor activity
JP2022141700A (ja) * 2016-06-07 2022-09-29 マックス－デルブリュック－セントルム フュール モレキュラー メディツィン イン デア ヘルムホルツ－ゲマインシャフト キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ－ｔ細胞
US12351640B2 (en) 2016-06-07 2025-07-08 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
WO2017211900A1 (en) * 2016-06-07 2017-12-14 Max-Delbrück-Centrum für Molekulare Medizin Chimeric antigen receptor and car-t cells that bind bcma
JP2019527537A (ja) * 2016-06-07 2019-10-03 マックス−デルブリュック−セントルム フュール モレキュラー メディツィン イン デア ヘルムホルツ−ゲマインシャフト キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ−ｔ細胞
US12048718B2 (en) 2016-06-07 2024-07-30 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
JP7646604B2 (ja) 2016-06-07 2025-03-17 マックス－デルブリュック－セントルム フュール モレキュラー メディツィン イン デア ヘルムホルツ－ゲマインシャフト キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ－ｔ細胞
JP2024178217A (ja) * 2016-06-07 2024-12-24 マックス－デルブリュック－セントルム フュール モレキュラー メディツィン イン デア ヘルムホルツ－ゲマインシャフト キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ－ｔ細胞
US11896615B2 (en) 2016-10-13 2024-02-13 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
US11739129B2 (en) 2016-10-21 2023-08-29 Washington University AP4 and methods of promoting T cell activation
WO2018075941A1 (en) * 2016-10-21 2018-04-26 Washington University Ap4 and methods of promoting t cell activation
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
JP2020505034A (ja) * 2017-01-20 2020-02-20 ジュノ セラピューティクス ゲーエムベーハー 細胞表面コンジュゲートならびに関連する細胞組成物および方法
US11517627B2 (en) 2017-01-20 2022-12-06 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
US12275787B2 (en) 2017-06-21 2025-04-15 Icell Gene Therapeutics Llc Chimeric antigen receptors (CARs), compositions and methods thereof
US12121527B2 (en) 2017-08-07 2024-10-22 Nbe-Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
US10758556B2 (en) 2017-08-07 2020-09-01 Nbe-Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
US12491153B2 (en) 2018-01-03 2025-12-09 Qu Biologics Inc. Innate targeting of adoptive cellular therapies
US12268741B2 (en) 2019-01-29 2025-04-08 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity

Also Published As

Publication number Publication date
US20220380461A1 (en) 2022-12-01
RU2016143389A3 (enExample) 2018-12-04
US20170015746A1 (en) 2017-01-19
US20220372140A1 (en) 2022-11-24
US10266592B2 (en) 2019-04-23
RU2752275C2 (ru) 2021-07-26
JP2020195380A (ja) 2020-12-10
WO2015157391A1 (en) 2015-10-15
US12448445B2 (en) 2025-10-21
ES2867224T3 (es) 2021-10-20
IL248243A0 (en) 2016-11-30
WO2015157399A9 (en) 2016-11-24
IL297591A (en) 2022-12-01
NZ739448A (en) 2019-10-25
JP7148580B2 (ja) 2022-10-05
JP7106610B2 (ja) 2022-07-26
US20170152297A1 (en) 2017-06-01
EP3954708A1 (en) 2022-02-16
EP3943507A1 (en) 2022-01-26
JP6765967B2 (ja) 2020-10-14
EP3129480A4 (en) 2017-08-16
IL248243B2 (en) 2024-04-01
IL248229A (en) 2016-11-30
RU2016143388A3 (enExample) 2018-11-30
AU2015243922A1 (en) 2016-11-03
AU2015243882A1 (en) 2016-11-03
CN106661570B (zh) 2020-02-07
CA2945303A1 (en) 2015-10-15
RU2751921C2 (ru) 2021-07-20
JP2017518037A (ja) 2017-07-06
MY186846A (en) 2021-08-26
JP7508516B2 (ja) 2024-07-01
JP6788573B2 (ja) 2020-11-25
BR112016023517A2 (pt) 2017-10-17
KR20220051024A (ko) 2022-04-25
BR112016023507A2 (pt) 2017-10-17
JP2022184989A (ja) 2022-12-13
MX2016013144A (es) 2017-04-27
ZA201607053B (en) 2025-03-26
US12202897B2 (en) 2025-01-21
US20210002364A1 (en) 2021-01-07
AU2015243920B2 (en) 2020-10-08
CN106573969A (zh) 2017-04-19
AU2021201679B2 (en) 2023-05-04
KR20230038310A (ko) 2023-03-17
US12258397B2 (en) 2025-03-25
EP3129480A1 (en) 2017-02-15
CN112877291A (zh) 2021-06-01
SG10201808833XA (en) 2018-11-29
JP2017513520A (ja) 2017-06-01
KR20160144432A (ko) 2016-12-16
US20180009891A1 (en) 2018-01-11
IL248238B2 (en) 2025-02-01
KR102730216B1 (ko) 2024-11-14
IL248235A0 (en) 2016-11-30
AU2015243882B2 (en) 2020-03-12
JP2022153456A (ja) 2022-10-12
EP3129405A1 (en) 2017-02-15
SG10201808811QA (en) 2018-11-29
JP6772068B2 (ja) 2020-10-21
JP7062720B2 (ja) 2022-05-06
WO2015157384A1 (en) 2015-10-15
KR102618955B9 (ko) 2024-08-12
BR112016023513A2 (pt) 2017-10-17
CN106574246A (zh) 2017-04-19
EP4056201A1 (en) 2022-09-14
US20170267742A1 (en) 2017-09-21
KR102463529B9 (ko) 2024-07-31
RU2016143388A (ru) 2018-05-14
IL248229B2 (en) 2023-05-01
KR102509481B1 (ko) 2023-03-10
SG11201608396YA (en) 2016-11-29
SA516380056B1 (ar) 2021-07-04
SG11201608393TA (en) 2016-11-29
JP2017515464A (ja) 2017-06-15
MX2016013158A (es) 2017-04-27
NZ725079A (en) 2018-03-23
CN106661570A8 (zh) 2017-07-04
JP6765968B2 (ja) 2020-10-07
PH12016502012A1 (en) 2017-01-09
US20210371517A1 (en) 2021-12-02
JP2021000117A (ja) 2021-01-07
CA2945308C (en) 2023-10-31
PH12016502010A1 (en) 2017-01-09
SG11201608395PA (en) 2016-11-29
CA2945320A1 (en) 2015-10-15
EP3129399A4 (en) 2017-11-08
EP3129053A1 (en) 2017-02-15
AU2015243922B2 (en) 2021-08-05
SG10201808825XA (en) 2018-11-29
WO2015157386A1 (en) 2015-10-15
AU2015243927A1 (en) 2016-11-03
CA2945308A1 (en) 2015-10-15
US10611837B2 (en) 2020-04-07
US20210139583A1 (en) 2021-05-13
RU2751920C2 (ru) 2021-07-20
IL248235B (en) 2021-01-31
EP3129471A1 (en) 2017-02-15
MX2016013149A (es) 2017-04-27
BR112016023500B1 (pt) 2024-04-30
AU2015243849A9 (en) 2019-07-25
US11155616B2 (en) 2021-10-26
PH12016502009A1 (en) 2017-01-09
JP7402933B2 (ja) 2023-12-21
PH12016502009B1 (en) 2022-07-22
EP3129405B1 (en) 2021-02-24
CN106661570A (zh) 2017-05-10
MY184163A (en) 2021-03-24
JP2017513470A (ja) 2017-06-01
CA2945302A1 (en) 2015-10-15
BR112016023500A2 (pt) 2017-10-17
AU2021200007A1 (en) 2021-03-04
US10865242B2 (en) 2020-12-15
EP3129405A4 (en) 2017-08-09
EP3129471A4 (en) 2017-11-08
CA2945305A1 (en) 2015-10-15
MY192522A (en) 2022-08-25
MX2022010807A (es) 2022-09-27
KR20160144430A (ko) 2016-12-16
CA2945305C (en) 2023-10-17
PH12016502010B1 (en) 2023-08-16
KR102618955B1 (ko) 2023-12-27
IL248238A0 (en) 2016-11-30
RU2016143385A3 (enExample) 2018-11-30
JP2017512484A (ja) 2017-05-25
RU2729112C2 (ru) 2020-08-04
IL248229B1 (en) 2023-01-01
RU2016143384A3 (enExample) 2018-11-30
PH12016502011A1 (en) 2017-01-09
RU2016143384A (ru) 2018-05-11
KR20220153100A (ko) 2022-11-17
CN106535934A (zh) 2017-03-22
JP2022109953A (ja) 2022-07-28
KR102600544B1 (ko) 2023-11-09
KR102463529B1 (ko) 2022-11-07
KR20160143762A (ko) 2016-12-14
RU2016143381A3 (enExample) 2018-11-30
EP3129399A1 (en) 2017-02-15
AU2021200007B2 (en) 2024-08-29
IL297591B1 (en) 2025-01-01
IL248238B1 (en) 2024-10-01
AU2021273652A1 (en) 2021-12-16
AU2015243849A1 (en) 2016-11-03
JP7542270B2 (ja) 2024-08-30
JP2021036867A (ja) 2021-03-11
RU2016143381A (ru) 2018-05-11
KR102508166B1 (ko) 2023-03-13
PH12016502011B1 (en) 2022-06-17
US20220064292A1 (en) 2022-03-03
ES2880932T3 (es) 2021-11-26
IL297591B2 (en) 2025-05-01
SG11201608392WA (en) 2016-11-29
MX387465B (es) 2025-03-18
MX389797B (es) 2025-03-20
RU2016143385A (ru) 2018-05-15
AU2015243927B2 (en) 2021-09-02
MY185678A (en) 2021-05-30
EP3129053A4 (en) 2017-11-08
US20190248891A1 (en) 2019-08-15
KR20160138298A (ko) 2016-12-02
KR102387243B1 (ko) 2022-04-14
JP6788573B6 (ja) 2020-12-16
CN106536558A (zh) 2017-03-22
MX395574B (es) 2025-03-25
AU2015243849B2 (en) 2020-12-17
NZ758289A (en) 2024-01-26
JP7093385B2 (ja) 2022-06-29
CA2945303C (en) 2024-02-13
BR112016023523A2 (pt) 2017-10-17
IL248243B1 (en) 2023-12-01
ZA201607060B (en) 2024-05-30
AU2015243882C1 (en) 2024-07-25
KR102387243B9 (ko) 2023-07-10
SG10201808819XA (en) 2018-11-29
CN113528581A (zh) 2021-10-22
AU2015243920A1 (en) 2016-11-03
RU2016143389A (ru) 2018-05-15
CN106573969B (zh) 2021-07-30
NZ725081A (en) 2018-02-23
WO2015157432A1 (en) 2015-10-15
US11414486B2 (en) 2022-08-16
ZA201607061B (en) 2024-05-30
MX2016013159A (es) 2017-04-27
JP2021019589A (ja) 2021-02-18
EP3129399B1 (en) 2021-05-26
KR20160144431A (ko) 2016-12-16
MX2016013160A (es) 2017-02-09
US20170029774A1 (en) 2017-02-02
AU2021201679A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
US12448445B2 (en) Transgene genetic tags and methods of use
EP4537839B1 (en) Method and compositions for cellular immunotherapy
JP2024016215A (ja) 免疫細胞の有効性および増大を改善する方法
HK40069668A (en) Transgene genetic tags and methods of use
RU2822461C1 (ru) Трансгенные генетические метки и способы применения
HK1233273B (en) Transgene genetic tags and methods of use
HK40051816B (en) Method and compositions for cellular immunotherapy
BR112016023507B1 (pt) Polipeptídeo isolado que compreende um domínio extracelular de um polipeptídeo her2
HK1212205B (en) Method and compositions for cellular immunotherapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15776745

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 248238

Country of ref document: IL

Ref document number: MX/A/2016/013160

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2945308

Country of ref document: CA

Ref document number: 2016561722

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12016502011

Country of ref document: PH

REEP Request for entry into the european phase

Ref document number: 2015776745

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015776745

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016023507

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2015243849

Country of ref document: AU

Date of ref document: 20150408

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20167031068

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016143384

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112016023507

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20161007

WWR Wipo information: refused in national office

Ref document number: 518391336

Country of ref document: SA

WWW Wipo information: withdrawn in national office

Ref document number: 725079

Country of ref document: NZ